Fresenius Medical Care AG & Co. KGaA (FMS) 6-K 5 Nov 13 2013 Q3 Current report (foreign) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013
Document and Entity Information [Abstract]	'
Document period end date	30-Sep-13
Amendment flag	'false
Entity registrant name	'FRESENIUS MEDICAL CARE AG & Co. KGaA
Entity current reporting status	'Yes
Entity voluntary filers	'Yes
Entity central index key	'0001333141
Document type	'6-K
Current fiscal year end date	'--12-31
Entity filer category	'Large Accelerated Filer
Entity well known seasoned issuer	'Yes
Entity common stock shares outstanding	302,843,085
Entity public float	$17,790,161,435
Document Fiscal Year Focus	'2013
Document Fiscal Period Focus	'Q3

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net revenue:	'	'	'	'
Dialysis Care Revenue	$2,886,742,000	$2,674,893,000	$8,439,921,000	$7,894,374,000
Valuation Allowances and Reserves, Adjustments	73,590,000	69,503,000	205,137,000	206,665,000
Net Dialysis care revenue	2,813,152,000	2,605,390,000	8,234,784,000	7,687,709,000
Dialysis Products Revenue	852,980,000	812,548,000	2,507,784,000	2,406,957,000
Net revenue	3,666,132,000	3,417,938,000	10,742,568,000	10,094,666,000
Costs of revenue:	'	'	'	'
Dialysis Care Cost of Revenue	2,097,751,000	1,917,303,000	6,139,317,000	5,662,376,000
Dialysis Products Cost of Revenue	399,252,000	388,324,000	1,166,231,000	1,123,596,000
Cost of revenues	2,497,003,000	2,305,627,000	7,305,548,000	6,785,972,000
Gross profit	1,169,129,000	1,112,311,000	3,437,020,000	3,308,694,000
Operating expenses:	'	'	'	'
Selling, general and administrative	584,549,000	522,177,000	1,771,619,000	1,614,625,000
Research and development	33,211,000	27,867,000	94,504,000	83,327,000
Income from equity method investees	-5,294,000	-5,317,000	-14,518,000	-14,672,000
Gain on the sale of dialysis clinics	597,000	58,000	9,397,000	'
Operating income	557,260,000	567,642,000	1,594,812,000	1,659,433,000
Other (income) expense:	'	'	'	'
Interest income	-8,740,000	-7,210,000	-25,982,000	-40,012,000
Interest expense	111,912,000	115,175,000	336,434,000	351,052,000
Investment gain	0	0	0	139,600,000
Income before income taxes	454,088,000	459,677,000	1,284,360,000	1,487,993,000
Income tax expense	148,259,000	153,036,000	420,873,000	462,354,000
Net Income	305,829,000	306,641,000	863,487,000	1,025,639,000
Less: Net income attributable to noncontrolling interests	32,855,000	36,779,000	102,490,000	95,942,000
Net Income attributable to the Company	272,974,000	269,862,000	760,997,000	929,697,000
Earning Per Share Diluted	$0.90	$0.88	$2.49	$3.03

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	$305,829	$306,641	$863,487	$1,025,639
Other comprehensive income loss derivatives qualifying as hedges before tax	-531	6,651	19,359	14,893
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	6,318	4,794	19,095	13,537
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	30,460	80,407	-96,902	32,791
Other comprehensive income loss tax	-2,517	-4,576	-12,431	-28,534
Other comprehensive income (loss), net of tax	33,730	87,276	-70,879	32,687
Total comprehensive income	339,559	393,917	792,608	1,058,326
Comprehensive income attributable to Noncontrolling interests	33,619	37,934	100,936	97,183
Comprehensive income attributable to the Company	$305,940	$355,983	$691,672	$961,143

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$602,155	$688,040
Trade accounts receivable less allowance for doubtful accounts of $353,082 in 2013 and $328,893 in 2012	3,001,900	3,019,424
Accounts receivable from related parties	141,272	137,809
Inventories	1,053,355	1,036,809
Prepaid expenses and other current assets	947,544	937,761
Deferred tax asset, current	297,949	307,613
Total current assets	6,044,175	6,127,456
Property, plant and equipment, net	3,007,904	2,940,603
Intangible assets	671,402	710,116
Goodwill	11,520,812	11,421,889
Deferred tax asset, non-current	141,288	133,753
Equity Method Investments	639,903	637,373
Other assets	509,036	354,808
Total assets	22,534,520	22,325,998
Current liabilities:	'	'
Accounts payable	505,405	622,294
Accounts payable to related parties	110,252	123,350
Accrued expenses and other current liabilities	1,888,529	1,787,471
Short-term borrowings and other financial liabilities	112,489	117,850
Short-term borrowings from related parties	73,048	3,973
Current portion of long-term debt and capital lease obligations	471,561	334,747
Income tax payable, current	195,139	150,003
Deferred tax liability, current	33,614	30,303
Total current liabilities	3,390,037	3,169,991
Total long-term debt less current maturities	7,772,303	7,785,740
Other liabilities	302,755	260,257
Pension liabilities	474,856	457,673
Income tax payable, non-current	193,432	201,642
Deferred tax liability, non-current	662,627	664,001
Long term debt from related parties	'	56,174
Total liabilities	12,796,010	12,595,478
Noncontrolling interests subject to put provisions	641,021	523,260
Company shareholders' equity:	'	'
Preferred stock, no par value, 1.00 Euro nominal value, 7,066,522 shares authorized, 3,973,333 issued and outstanding as of December 31, 2012 (see note 7)	0	4,462
Common stock, no par value, 1.00 Euro nominal value, 392,462,972 shares authorized, 308,317,517 issued and 300,768,566 outstanding	381,488	374,915
Treasury Stock	505,014	0
Additional paid-in capital	3,510,965	3,491,581
Retained earnings	6,028,524	5,563,661
Accumulated other comprehensive (loss)	-561,438	-492,113
Total Company shareholders' equity	8,854,525	8,942,506
Minority interest	242,964	264,754
Total equity	9,097,489	9,207,260
Total liabilities and equity	$22,534,520	$22,325,998

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Consolidated Balance Sheets	'	'
Trade accounts receivable allowance for doubtful accounts	$353,082	$328,893
Preferred stock authorized	7,066,522	'
Preferred stock issued	3,973,333	'
Preferred stock outstanding	3,973,333	'
Common stock authorized	392,465,972	'
Common stock issued	308,317,517	'
Common stock outstanding	308,317,517	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating Activities:	'	'
Net Income	$863,487	$1,025,639
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	479,433	446,463
Change in deferred taxes, net	-14,204	71,388
(Gain) loss on sale of fixed assets	2,995	2,213
Stock Option Compensation Expense	18,484	19,685
Cash outflow from hedging	-4,040	-13,903
Investment gain	0	139,600
Dividend income from equity method investees	10,790	25,083
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Trade accounts receivable, net	-15,470	-2,890
Inventories, net	-20,109	-43,214
Prepaid expenses, other current and non-current assets	55,164	144,724
Accounts receivable, related parties	-2,232	-26,281
Accounts payable, related parties	-13,933	16,257
Accounts payable, accrued expenses and other current and non-current liabilities	78,743	59,020
Income tax payable	16,309	-83,175
Net cash provided by (used in) operating activities	1,446,020	1,467,374
Investing Activities:	'	'
Purchases of property, plant and equipment	-512,476	-449,962
Proceeds from sale of property, plant and equipment	18,583	11,292
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	-297,456	-1,788,831
Proceeds from divestitures	17,984	231,747
Net cash (used in) provided by investing activities	-773,365	-1,995,754
Financing Activities:	'	'
Proceeds from short-term borrowings and other financial liabilities	78,316	119,113
Repayments of short-term borrowings and other financial liabilities	-78,555	-112,419
Proceeds from short-term borrowings from related parties	16,464	79,207
Repayments of short-term borrowings from related parties	-5,836	-13,576
Proceeds from long-term debt and capital lease obligations (net of debt issuance costs and other hedging costs of $156,391 in 2012)	337,137	2,054,420
Repayments of long-term debt and capital lease obligations	-325,912	-1,158,335
Increase (decrease) of accounts receivable securitization program	37,000	12,500
Proceeds from exercise of stock options	74,875	94,539
Proceeds from conversion of preference shares into ordinary shares	34,784	0
Purchase of treasury stock	-505,014	0
Payment of dividends [N]	-296,134	-271,733
Distributions to Noncontrolling interests	-162,239	-131,783
Contributions from noncontrolling interests	52,357	15,167
Cash provided by (used in) financing activities	-742,757	687,100
Effect of exchange rate changes on cash and cash equivalents	-15,783	3,039
Cash and Cash Equivalents:	'	'
Net (decrease) in cash and cash equivalents	-85,885	161,759
Cash and cash equivalents at beginning of period	688,040	457,292
Cash and cash equivalents at end of period	$602,155	$619,051

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Preferred Stock, No par value [Member]	Common Stock, No par value [Member]	Treasury Stock Equity	Additional paid in capital [Member]	Retained earnings [Member]	Accumulated other comprehensive income (loss) [Member]	Total FMC-AG and Co. KGaA [Member]	Noncontrolling interests not subject to put provisions [Member]
In Thousands, except Share data, unless otherwise specified
Shareholders equity at Dec. 31, 2011	$8,061,017	$4,452	$371,649	'	$3,362,633	$4,648,585	($485,767)	$7,901,552	'
Shares issued at Dec. 31, 2011	'	3,965,691	300,164,922	'	'	'	'	'	'
Proceeds from exercise of options and related tax effects	113,786	10	3,266	'	110,510	'	'	113,786	159,465
Shares from exercise of options and related tax effects	'	7,642	2,574,836	'	'	'	'	'	'
Compensation expense related to stock options	26,476	'	'	'	26,476	'	'	26,476	'
Dividends paid	271,733	'	'	'	'	271,733	'	271,733	'
Minority interest increase from stock issuance	59,787	'	'	'	-26,918	'	'	-26,918	86,705
Minority interest decrease from distributions to noncontrolling interest holders	26,428	'	'	'	'	'	'	'	26,428
Changes in fair value of noncontrolling interests	18,880	'	'	'	18,880	'	'	18,880	'
Comprehensive income net of tax including portion attributable to noncontrolling interest abstract	'	'	'	'	'	'	'	'	'
Other comprehensive income loss net of tax period increase decrease less amounts attributable to noncontrolling interests subject to put provisions	-6,784	'	'	'	'	'	-6,346	-6,346	-438
Profit loss less amounts attributable to noncontrolling interests subject to put provisions	1,232,259	'	'	'	'	1,186,809	'	1,186,809	45,450
Comprehensive income net of tax including portion attributable to noncontrolling interest less amounts attributable to noncontrolling interests subject to put provisions	1,225,475	'	'	'	'	'	'	1,180,463	45,012
Shareholders equity at Dec. 31, 2012	9,207,260	'	'	'	3,491,581	5,563,661	-492,113	8,942,506	264,754
Proceeds from exercise of options and related tax effects	72,105	3	2,108	'	69,994	'	'	72,105	'
Shares from exercise of options and related tax effects	2,200	'	1,602,226	'	'	'	'	'	'
Proceeds from conversion of preference shares	34,784	-4,465	4,465	'	34,784	'	'	34,784	'
Preference share conversion	'	-3,975,533	3,975,533	'	'	'	'	'	'
Compensation expense related to stock options	-18,484	'	'	'	-18,484	'	'	-18,484	'
Dividends paid	296,134	'	'	'	'	296,134	'	'	'
treasury stock value	-505,014	'	'	-7,548,951	'	'	'	'	'
treasury stock shares	'	'	'	-505,014	'	'	'	'	'
Minority interest increase from stock issuance	-16,916	'	'	'	1,511	'	'	1,511	-18,427
Minority interest decrease from distributions to noncontrolling interest holders	-26,262	'	'	'	'	'	'	296,134	-26,262
Changes in fair value of noncontrolling interests	-105,389	'	'	'	-105,389	'	'	-105,389	'
Comprehensive income net of tax including portion attributable to noncontrolling interest abstract	'	'	'	'	'	'	'	'	'
Other comprehensive income loss net of tax period increase decrease less amounts attributable to noncontrolling interests subject to put provisions	-71,449	'	'	'	'	'	-69,325	-69,325	-2,124
Profit loss less amounts attributable to noncontrolling interests subject to put provisions	786,020	'	'	'	'	760,997	'	760,997	25,023
Comprehensive income net of tax including portion attributable to noncontrolling interest less amounts attributable to noncontrolling interests subject to put provisions	714,571	'	'	'	'	'	'	691,672	22,899
Shareholders equity at Sep. 30, 2013	$9,097,489	$0	$381,488	($505,014)	$3,510,965	$6,028,524	($561,438)	$8,854,525	$242,964
Shares issued at Sep. 30, 2013	'	0	'	'	'	'	'	'	'

The_Company_Basis_of_Presentat

The Company, Basis of Presentation, Healthcare Reform and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
The Company and Basis of Presentation	'
	1. The Company and Basis of Presentation
	The Company
	Fresenius Medical Care AG & Co. KGaA (“FMC-AG & Co. KGaA” or the “Company”), a German partnership limited by shares (Kommanditgesellschaft auf Aktien), is the world's largest kidney dialysis company, operating in both the field of dialysis care and the field of dialysis products for the treatment of end-stage renal disease (“ESRD”). The Company's dialysis care business, in addition to providing dialysis treatments, includes pharmacy services and vascular access surgery services (together, the “Expanded Services”). The Company's dialysis products business includes manufacturing and distributing products and equipment for the treatment of ESRD. The Company's dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a broad range of products. In addition, the Company sells dialysis products to other dialysis service providers. Fresenius Medical Care Holdings, Inc. (“FMCH”), 100% indirectly owned by the Company, located in the United States and our largest subsidiary, also provides laboratory testing services, and inpatient dialysis services as well as other services under contract to hospitals.
	In these unaudited consolidated financial statements, “FMC-AG & Co. KGaA,” or the “Company,” “we,” “us” or “our” refers to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. The term “North America Segment” refers to the North America operating segment. The term “International Segment” refers to the combined Europe, Middle East, Africa and Latin America (“EMEALA”) operating segment and the Asia-Pacific operating segment.
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
	The consolidated financial statements at September 30, 2013 and for the three and nine-months ended September 30, 2013 and 2012 contained in this report are unaudited and should be read in conjunction with the consolidated financial statements contained in the Company's 2012 Annual Report on Form 20-F. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Such financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are of a normal recurring nature.
	The accounting policies applied in the accompanying consolidated financial statements are the same as those applied in the consolidated financial statements at and for the year ended December 31, 2012, contained in the Company's 2012 Annual Report on Form 20-F.
	The results of operations for the three and nine-months periods ended September 30, 2013 are not necessarily indicative of the results of operations for the year ending December 31, 2013.

Acquisition_of_Liberty_Dialysi

Acquisition of Liberty Dialysis Holdings	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Acquisition of Liberty Dialysis Holdings [Text Block]	'
	2. Acquisition of Liberty Dialysis Holdings, Inc.
	On February 28, 2012, the Company acquired 100% of the equity of Liberty Dialysis Holdings, Inc. (“LD Holdings”), the owner of Liberty Dialysis and owner of a 51% stake in Renal Advantage Partners, LLC (the “Liberty Acquisition”). The Company accounted for this transaction as a business combination and finalized the acquisition accounting on February 28, 2013.
	Total consideration for the Liberty Acquisition was $2,181,358, consisting of $1,696,659 cash, net of cash acquired and $484,699 non-cash consideration. Accounting standards for business combinations require previously held equity interests to be fair valued at the time of the acquisition with the difference to book value to be recognized as a gain or loss in income. Prior to the Liberty Acquisition, the Company had a 49% equity investment in Renal Advantage Partners, LLC, the fair value of which, $201,915, was included as part of the non-cash consideration. The fair value was determined based on the discounted cash flow method, utilizing a discount rate of approximately 13%. In addition to the Company's investment, it also had a loan receivable from Renal Advantage Partners, LLC of $279,793, at a fair value of $282,784, which was retired as part of the transaction.
	The following table summarizes the final fair values of assets acquired and liabilities assumed at the date of the acquisition. Any adjustments to acquisition accounting from December 31, 2012 until finalization, net of related income tax effects, were recorded with a corresponding adjustment to goodwill:
	Assets held for sale		$	164,068
	Trade accounts receivable			149,219
	Other current assets			17,458
	Deferred tax assets			14,932
	Property, plant and equipment			168,335
	Intangible assets and other assets			84,556
	Goodwill			2,003,465
	Accounts payable, accrued expenses and other current liabilities			-105,403
	Income tax payable and deferred taxes			-33,597
	Short-term borrowings, other financial liabilities, long-term debt and capital lease obligations			-72,101
	Other liabilities			-39,923
	Noncontrolling interests (subject and not subject to put provisions)			-169,651
	Total acquisition cost		$	2,181,358
	Less non-cash contributions at fair value
		Investment at acquisition date		-201,915
		Long-term Notes Receivable		-282,784
	Total non-cash items		$	-484,699
	Net Cash paid		$	1,696,659
	The amortizable intangible assets acquired in this acquisition have weighted average useful lives of 6-8 years.
	Goodwill in the amount of $2,003,465 was acquired as part of the Liberty Acquisition and was allocated to the North America Segment. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill arises principally due to the fair value placed on an estimated stream of future cash flows versus building a similar franchise. Of the goodwill recognized in this acquisition, approximately $436,000 is deductible for tax purposes and will be amortized over a 15 year period beginning on the date of the acquisition.
	The noncontrolling interests acquired as part of the acquisition are stated at fair value based upon contractual multiples typically utilized by the Company for such arrangements as well as the Company's overall experience
	The fair valuation of the Company's investment at the time of the Liberty Acquisition resulted in a non-taxable gain of $139,600. The retirement of the loan receivable resulted in a benefit of $8,501.
	Divestitures
	In connection with the Federal Trade Commission's consent order relating to the Liberty Acquisition, the Company agreed to divest a total of 62 renal dialysis centers. 61 clinics were sold by the end of the third quarter of 2012, 24 of which were FMC-AG & Co. KGaA clinics which generated a gain of $33,455. This gain did not change during the period ended December 31, 2012 and was included in the Consolidated Statements of Income. In the second quarter of 2013, the remaining clinic was sold for a gain of $7,705. The 38 clinics acquired and subsequently sold were categorized as Assets held for sale in the table above at the time of the Liberty Acquisition.

Acquisition_of_Liberty_Dialysi1

Acquisition of Liberty Dialysis Holdings- Pro Forma	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Acquisition Of Liberty Dialysis Holding [TextBlock]	'
	Pro Forma Financial Information
	The following financial information, on a pro forma basis, reflects the consolidated results of operations as if the Liberty Acquisition and the divestitures described above had been consummated on January 1, 2011. The pro forma information includes adjustments primarily for elimination of the investment gain and the gain from the retirement of debt. The pro-forma financial information is not necessarily indicative of the results of operations as it would have been had the transactions been consummated on January 1, 2011.
			For the three months ended September 30,		For the nine months ended September 30,
			2012			2012
	Net revenue		$	3,415,472	$	10,197,670
	Net income attributable to shareholders of FMC-AG & Co. KGaA			268,467		797,867
	Income per ordinary share
		Basic	$	0.88	$	2.62
		Fully diluted	$	0.87	$	2.6

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Related Party Transactions	'
	3. Related Party Transactions
	The Company's parent, Fresenius SE & Co. KGaA (“Fresenius SE”), a German partnership limited by shares, owns 100% of the share capital of Fresenius Medical Care Management AG, the Company's general partner (“General Partner”). Fresenius SE, the Company's largest shareholder, owns approximately 31.4% of the Company's shares at September 30, 2013, excluding the shares purchased through the share buyback program as they are not considered to be outstanding shares (see Note 8, Earnings Per Share).
	a)       Service and Lease Agreements
	The Company is party to service agreements with Fresenius SE and certain of its affiliates (collectively the “Fresenius SE Companies”) to receive services, including, but not limited to: administrative services, management information services, employee benefit administration, insurance, information technology services, tax services and treasury management services. In 2013, the Company entered into a new five year information technology services agreement, expiring in 2018, which has an automatic continuation for an additional 5 year period with short-term continuations thereafter unless either party terminates the agreement as of the end of the then-current term. The Company has complied with all corporate governance procedures for this agreement (for information on corporate governance, see Item 16G, “Corporate Governance” in our Annual Report on Form 20-F for the year ended December 31, 2012). During the nine-months ended September 30, 2013 and 2012, amounts charged by Fresenius SE to the Company under the terms of these agreements were $78,215 and $60,634, respectively. The Company also provides certain services to the Fresenius SE Companies, including research and development, central purchasing and warehousing. The Company charged $4,925 and $4,396 for services rendered to the Fresenius SE Companies during the first nine months of 2013 and 2012 respectively.
	Under real estate operating lease agreements entered into with the Fresenius SE Companies, which are leases for the corporate headquarters in Bad Homburg, Germany and production sites in Schweinfurt and St. Wendel, Germany, the Company paid the Fresenius SE Companies $20,037 and $18,779 during the nine months ended September 30, 2013 and 2012, respectively. The majority of the leases expire in 2016 and contain renewal options.
	The Company's Articles of Association provide that the General Partner shall be reimbursed for any and all expenses in connection with management of the Company's business, including remuneration of the members of the General Partner's supervisory board and the General Partner's management board. The aggregate amount reimbursed to the General Partner was $12,219 and $12,243, respectively, for its management services during the nine months ended September 30, 2013 and 2012.
	b)       Products
	For the first nine months of 2013 and 2012, the Company sold products to the Fresenius SE Companies for $22,651 and $16,802, respectively. During the same periods, the Company made purchases from the Fresenius SE Companies in the amount of $27,854 and $35,572, respectively.
	In addition to the purchases noted above, the Company currently purchases heparin supplied by Fresenius Kabi USA, Inc. (“Kabi USA”), through an independent group purchasing organization (“GPO”). Kabi USA is wholly-owned by Fresenius Kabi AG, a wholly-owned subsidiary of Fresenius SE. The Company has no direct supply agreement with Kabi USA and does not submit purchase orders directly to Kabi USA. During the nine-months ended September 30, 2013 and 2012, FMCH acquired approximately $14,420 and $12,820, respectively, of heparin from Kabi USA, through the GPO contract, which was negotiated by the GPO at arm's length on behalf of all members of the GPO.
	c)       Financing Provided by and to Fresenius SE and the General Partner
	The Company receives short-term financing from and provides short-term financing to Fresenius SE. The Company also utilizes Fresenius SE's cash management system for the settlement of certain intercompany receivables and payables with its subsidiaries and other related parties.
	At September 30, 2013, the Company received a loan from Fresenius SE of €9,300 ($12,560 at September 30, 2013) at an interest rate of 1.503%. This loan repayment has been extended at an amount of €30,400 ($41,055 at September 30, 2013) and is currently due on November 29, 2013.
	On August 19, 2009, the Company borrowed €1,500 ($2,026 at September 30, 2013) from the General Partner at 1.335%. The loan repayment has been extended periodically and is currently due August 20, 2014 at an interest rate of 1.796%.
	At September 30, 2013, the Company had a Chinese Yuan Renminbi (“CNY”) loan of 357,769 ($58,462 at September 30, 2013) outstanding with a subsidiary of Fresenius SE at an interest rate of 6.1% and a maturity date of May 23, 2014.
	d) Other
	The Company, at September 30, 2013, had a receivable from Fresenius SE in the amount of €4,827 ($6,518 at September 30, 2013) resulting from being a party to a German trade tax group agreement with Fresenius SE for the fiscal years 1997-2001.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Inventories	'
	4. Inventories
	At September 30, 2013 and December 31, 2012, inventories consisted of the following:
				30-Sep-13		31-Dec-12
	Finished goods		$	646,659	$	627,338
	Raw materials and purchased components			192,352		171,373
	Health care supplies			127,715		154,840
	Work in process			86,629		83,258
		Inventories	$	1,053,355	$	1,036,809

Longterm_Debt_and_Capital_Leas

Long-term Debt and Capital Lease Obligations	6 Months Ended	9 Months Ended
	Jun. 30, 2013	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'	'
Long-term Debt and Capital Lease Obligations	'	'
	In addition, at September 30, 2013 and December 31, 2012, the Company had letters of credit outstanding in the amount of $10,615 and $77,188, respectively, under the revolving credit facility, which are not included above as part of the balance outstanding, but reduce the available borrowings under the revolving credit facility.	6. Long-Term Debt and Capital Lease Obligations and Long-Term Debt from Related Parties
	Accounts Receivable Facility Letters of Credit	At September 30, 2013 and December 31, 2012, long-term debt and capital lease obligations and long-term debt from related parties consisted of the following:
	The Company also had letters of credit outstanding under the accounts receivable facility in the amount of $65,622 as of September 30, 2013. These letters of credit are not included above as part of the balance outstanding at September 30, 2013; however, they reduce available borrowings under the accounts receivable facility.		30-Sep-13		31-Dec-12
		2012 Credit Agreement	$	2,869,194	$	2,659,340
		Senior Notes		4,786,706		4,743,442
		Euro Notes		45,579		51,951
		European Investment Bank Agreements		189,070		324,334
		Accounts receivable facility		199,000		162,000
		Capital lease obligations		23,171		15,618
		Other		131,144		163,802
		Long-term debt and capital lease obligations		8,243,864		8,120,487
		Less current maturities		-471,561		-334,747
		Long-term debt and capital lease obligations, less current portion		7,772,303		7,785,740
		Long-term debt from related parties		-		56,174
		Long-term debt and capital lease obligations and long-term debt from related parties	$	7,772,303	$	7,841,914
		2012 Credit Agreement
		The following table shows the available and outstanding amounts under the 2012 Credit Agreement at September 30, 2013 and at December 31, 2012:
			Maximum Amount Available September 30, 2013				Balance Outstanding September 30, 2013
		Revolving Credit USD	$	600,000	$	600,000	$	49,094	$	49,094
		Revolving Credit EUR	€	500,000	$	675,250	€	200,000	$	270,100
		Term Loan A	$	2,550,000	$	2,550,000	$	2,550,000	$	2,550,000
					$	3,825,250			$	2,869,194
			Maximum Amount Available December 31, 2012				Balance Outstanding December 31, 2012
		Revolving Credit USD	$	600,000	$	600,000	$	59,340	$	59,340
		Revolving Credit EUR	€	500,000	$	659,700	€	-	$	-
		Term Loan A	$	2,600,000	$	2,600,000	$	2,600,000	$	2,600,000
					$	3,859,700			$	2,659,340

Stock_Options

Stock Options	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Discloure of Compensation Related Costs Share Based Payments [Text Block]	'
	7. Stock Options
	On July 29, 2013 under the Long Term Incentive Program 2011, the Company awarded 2,110,388 stock options, including 328,680 stock options granted to members of the Management Board of Fresenius Medical Care Management AG (“Management Board”), the Company's general partner, at an exercise price of $66.03 (€49.76), a fair value of $11.84 each and a total fair value of $24,980 which will be amortized over the four-year vesting period. The Company also awarded 183,661 shares of phantom stock, including 25,006 shares of phantom stock granted to members of the Management Board at a measurement date fair value of $60.25 (€44.61) each and a total fair value of $11,065, which will be revalued if the fair value changes, and amortized over the four-year vesting period.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Earnings Per Share	'
	8. Earnings Per Ordinary Share
	The following table contains reconciliations of the numerators and denominators of the basic and diluted earnings per ordinary share computations for the three- and nine-months ended September 30, 2013 and 2012:
			For the three months ended September 30,					For the nine months ended September 30,
			2013		2012			2013			2012
	Numerators:
	Net income attributable to shareholders of FMC-AG & Co. KGaA		$	272,974	$	269,862		$	760,997		$	929,697
	less:
		Dividend preference on Preference shares		-		25			-			76
	Income available to all classes of shares		$	272,974	$	269,837		$	760,997		$	929,621
	Denominators:
	Weighted average number of:
	Ordinary shares outstanding			301,310,149		301,531,173			302,158,886			300,720,312
	Preference shares outstanding			-		3,971,607			2,590,857			3,968,082
	Total weighted average shares outstanding			301,310,149		305,502,780			304,749,743			304,688,394
	Potentially dilutive Ordinary shares			445,648		2,008,318			637,188			1,740,599
	Potentially dilutive Preference shares			-		17,392			-			17,209
	Total weighted average Ordinary shares outstanding assuming dilution			301,755,797		303,539,491			302,796,074			302,460,911
	Total weighted average Preference shares outstanding assuming dilution			-		3,988,999			2,590,857			3,985,291
	Basic income per Ordinary share		$	0.91	$	0.88		$	2.5		$	3.05
	Fully diluted income per Ordinary share		$	0.9	$	0.88		$	2.49		$	3.03
	On May 16, 2013, the Company held its Annual General Meeting and a separate Preference Shareholder Meeting during which resolutions on the conversion of the preference shares to ordinary shares were passed. The preference share conversion was effected on June 28, 2013 with 3,975,533 preference shares in the amount of €3,976 ($4,465) converted on a 1:1 basis to ordinary shares. In addition, 32,006 options associated with the preference shares were converted into options associated with ordinary shares.
	On July 5, 2013, the Company received a €27,000 ($34,784) premium from the largest former preference shareholder, a financial institution located outside the United States, for the conversion of their preference shares to ordinary shares. This amount was recorded as an increase in equity as of June 30, 2013 and the payment was received during the third quarter of 2013.
	Additionally, the Company completed a share buy-back program during the third quarter of 2013. The Company intended to repurchase ordinary shares in an aggregate value of up to €385,000 (approximately $500,000). At September 30, 2013, 7,548,951 shares had been repurchased in the amount of €384,966 ($505,014). These shares are restricted treasury stock which means there are no associated dividends or voting rights. These treasury shares will be used solely to either reduce the registered share capital of the Company by cancellation of the acquired shares, or to fulfill employee participation programs of the Company.
	The following tabular disclosure provides the shares repurchased as of September 30, 2013:
	Period		Average price paid per share		Average price paid per share(1)		Total number of shares purchased as part of publicly announced plans or programs			Total Value of Shares Repurchased(4)			Total Value of Shares Repurchased(2), (4)			Maximum value of shares that may yet be purchased under plans or programs as of the end of the period(3)
				in €		in $					in €			in $		in €		in $
											in thousands
	May-13		€	52.96	$	68.48		1,078,255		€	57,107		$	73,842	€	327,893	$	426,458
	Jun-13		€	53.05	$	69.95		2,502,552		€	132,769		$	175,047	€	195,124	$	255,222
	Jul-13		€	49.42	$	64.63		2,972,770		€	146,916		$	192,124	€	48,208	$	63,996
	Aug-13		€	48.4	$	64.3		995,374		€	48,174		$	64,001	€	-	$	-
	Total		€	51	$	66.9		7,548,951		€	384,966		$	505,014
	(1) The dollar value is calculated using the daily exchange rate for the share repurchases made during the month.
	(2) The value of the shares repurchased in Dollar is calculated using the total value of the shares purchased in Euro converted using the daily exchange rate for the transactions.
	(3) The maximum Dollar value of the shares remaining is calculated using the maximum Euro value of shares that may yet be repurchased converted at the end of the month spot rate.
	(4) This amount is inclusive of fees (net of taxes) paid in the amount of approximately $106 (€ 81) for services rendered.

Employee_Benefit_Plans

Employee Benefit Plans	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Employee Benefit Plans	'
	9. Employee Benefit Plans
	The Company currently has two principal pension plans, one for German employees, the other covering employees in the United States, the latter of which was curtailed in 2002. Plan benefits are generally based on years of service and final salary. As there is no legal requirement in Germany to fund defined benefit plans, the Company's pension obligations in Germany are unfunded. Each year FMCH contributes to the plan covering United States employees at least the minimum required by the Employee Retirement Income Security Act of 1974, as amended.
	The following table provides the calculations of net periodic benefit cost for the three- and nine-months ended September 30, 2013 and 2012, respectively.
		Three months ended September 30,				Nine months ended September 30,
		2013		2012		2013		2012
	Components of net periodic benefit cost:
	Service cost	$	3,932	$	2,645	$	11,601	$	7,982
	Interest cost		6,635		6,590		20,130		19,528
	Expected return on plan assets		-3,415		-3,796		-10,215		-11,446
	Amortization of unrealized losses		6,318		4,794		19,095		13,537
	Net periodic benefit costs	$	13,470	$	10,233	$	40,611	$	29,601

Noncontrolling_Interests_Subje

Noncontrolling Interests Subject to Put Provisions	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Noncontrolling Interests Subject to Put Provisions	'
	10. Noncontrolling Interests Subject to Put Provisions
	The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, the development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions.
	At September 30, 2013 and December 31, 2012, the Company's potential obligations under these put options were $641,021 and $523,260, respectively, of which, at September 30, 2013, put options with an aggregate purchase obligation of $252,319 were exercisable. One put option was exercised for a total consideration of $3,100 during the first nine months of 2013.
	Following is a roll forward of noncontrolling interests subject to put provisions for the nine months ended September 30, 2013 and the year ended December 31, 2012:
		30-Sep-13		31-Dec-12
	Beginning balance as of January 1,	$	523,260	$	410,491
	Contributions to noncontrolling interests		-88,847		-114,536
	Purchase/ sale of noncontrolling interests		8,556		134,643
	Contributions from noncontrolling interests		14,626		16,565
	Changes in fair value of noncontrolling interests		105,389		-18,880
	Net income		77,467		94,718
	Other comprehensive income (loss)		570		259
	Ending balance as of September 30, 2013 and December 31, 2012	$	641,021	$	523,260

Patient_Service_Revenue

Patient Service Revenue	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Patient Service Revenue Text Block 1 [Text Block]	'
	11. Sources of Revenue
	Below is a table showing the sources of our U.S. patient service revenue (net of contractual allowance and discounts but before patient service bad debt provision), included in the Company's dialysis care revenue, for the nine-months ended September 30, 2013 and 2012. Outside of the U.S., the Company does not recognize patient service revenue at the time the services are rendered without assessing the patient's ability to pay. Accordingly, the additional disclosure requirements introduced with ASU 2011-07 only apply to the U.S. patient service revenue.
		For the nine months ended September 30,
			2013		2012
	Medicare ESRD program	$	3,258,043	$	2,955,411
	Private/alternative payors		2,833,762		2,671,895
	Medicaid and other government sources		288,878		287,726
	Hospitals		309,164		299,067
	Total patient service revenue	$	6,689,847	$	6,214,099

Financial_Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Financial Instruments	'
	13. Financial Instruments
	As a global supplier of dialysis services and products in more than 120 countries throughout the world, the Company is faced with a concentration of credit risks due to the nature of the reimbursement systems which are often provided by the governments of the countries in which the Company operates. Changes in reimbursement rates or the scope of coverage could have a material adverse effect on the Company's business, financial condition and results of operations and thus on its capacity to generate cash flow.
	Non-derivative Financial Instruments
	The following table presents the carrying amounts and fair values of the Company's non-derivative financial instruments at September 30, 2013, and December 31, 2012.
						September 30,						December 31,
						2013						2012
			Fair Value			Carrying			Fair			Carrying			Fair
			Hierarchy			Amount			Value			Amount			Value
	Assets
		Cash and cash equivalents	1		$	602,155			602,155		$	688,040			688,040
		Accounts Receivable(1)	2			3,143,172			3,143,172			3,157,233			3,157,233
		Long-term Notes Receivable	3			165,648			172,244			-			-
	Liabilities
		Accounts payable(1)	2			615,657			615,657			745,644			745,644
		Short-term borrowings(1)	2			185,537			185,537			121,823			121,823
		Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes	2			542,385			542,385			721,928			721,928
		2012 Credit Agreement	2			2,869,194			2,859,632			2,659,340			2,652,840
		Senior Notes	2			4,786,706			5,160,957			4,743,442			5,296,325
		Euro Notes	2			45,579			46,236			51,951			54,574
	Noncontrolling interests subject to put provisions		3			641,021			641,021			523,260			523,260
	(1) Also includes amounts from related parties.
	The carrying amounts in the table are included in the consolidated balance sheet under the indicated captions or in the case of long-term debt, in the captions shown in Note 6.
	The significant methods and assumptions used in estimating the fair values of non-derivative financial instruments are as follows:
	Cash and cash equivalents are stated at nominal value which equals the fair value.
	Short-term financial instruments such as accounts receivable, accounts payable and short-term borrowings are valued at their carrying amounts, which are reasonable estimates of the fair value due to the relatively short period to maturity of these instruments.
	The valuation of long-term notes receivable was determined using significant unobservable inputs. They were valued using a constructed index based upon similar instruments with comparable credit ratings, terms, tenor, interest rates and that are within the Company's industry. The Company tracked the prices of the constructed index from the note issuance date to the reporting date to determine fair value. See Note 5 for further information on the long-term notes receivable.
	The fair values of major long-term financial liabilities are calculated on the basis of market information. Instruments for which market quotes are available are measured using these quotes. The fair values of the other long-term financial liabilities are calculated at the present value of the respective future cash flows. To determine these present values, the prevailing interest rates and credit spreads for the Company as of the balance sheet date are used.
	The valuation of noncontrolling interests subject to put provisions is determined using significant unobservable inputs. See Note 10 for a discussion of the Company's methodology for estimating the fair value of these noncontrolling interests subject to put obligations.
	Currently, there is no indication that a decrease in the value of the Company's financing receivables is probable. Therefore, the allowances on credit losses of financing receivables are immaterial.
	Derivative Financial Instruments
	The Company is exposed to market risk from changes in foreign exchange rates and interest rates. In order to manage the risk of currency exchange rate and interest rate fluctuations, the Company enters into various hedging transactions by means of derivative instruments with highly rated financial institutions as authorized by the Company's General Partner. On a quarterly basis the Company performs an assessment of its counterparty credit risk. The Company currently considers this risk to be low. The Company's policy, which has been consistently followed, is that financial derivatives be used only for the purpose of hedging foreign currency and interest rate exposure.
	In certain instances, the Company enters into derivative contracts that do not qualify for hedge accounting but are utilized for economic purposes (“economic hedges”). The Company does not use financial instruments for trading purposes.
	The Company established guidelines for risk assessment procedures and controls for the use of financial instruments. They include a clear segregation of duties with regard to execution on one side and administration, accounting and controlling on the other.
	To reduce the credit risk arising from derivatives the Company concluded Master Netting Agreements with banks. Through such agreements, positive and negative fair values of the derivative contracts could be offset against one another if a partner becomes insolvent. This offsetting is valid for transactions where the aggregate amount of obligations owed to and receivable from are not equal. If insolvency occurs, the party which owes the larger amount is obliged to pay the other party the difference between the amounts owed in the form of one net payment.
	The Company elects not to offset the fair values of derivative financial instruments subject to master netting agreements in the Consolidated Balance Sheet.
	At September 30, 2013 and December 31, 2012, the Company had $16,181 and $32,044 of derivative financial assets subject to netting arrangements and $9,928 and $19,193 of derivative financial liabilities subject to netting arrangements. Offsetting these derivative financial instruments would have resulted in net assets of $11,242 and $20,773 as well as net liabilities of $4,989 and $7,922 at September 30, 2013 and December 31, 2012, respectively.
	Foreign Exchange Risk Management
	The Company conducts business on a global basis in various currencies, though a majority of its operations are in Germany and the United States. For financial reporting purposes, the Company has chosen the U.S. dollar as its reporting currency. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which the financial statements of the Company's international operations are maintained affect its results of operations and financial position as reported in its consolidated financial statements.
	The Company's exposure to market risk for changes in foreign exchange rates relates to transactions such as sales and purchases. The Company has significant amounts of sales of products invoiced in euro from its European manufacturing facilities to its other international operations and, to a lesser extent, sales of products invoiced in other non-functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the euro and the currency in which their local operations are conducted. For the purpose of hedging existing and foreseeable foreign exchange transaction exposures the Company enters into foreign exchange forward contracts and, on a small scale, foreign exchange options. At September 30, 2013 the Company had no foreign exchange options.
	Changes in the fair value of the effective portion of foreign exchange forward contracts designated and qualifying as cash flow hedges of forecasted product purchases and sales are reported in accumulated other comprehensive income (loss) (“AOCI”). Additionally, in connection with intercompany loans in foreign currency, the Company uses foreign exchange swaps thus assuring that no foreign exchange risks arise from those loans, which, if they qualify for cash flow hedge accounting, are also reported in AOCI. These amounts recorded in AOCI are subsequently reclassified into earnings as a component of cost of revenues for those contracts that hedge product purchases or as an adjustment of interest income/expense for those contracts that hedge loans, in the same period in which the hedged transaction affects earnings. The notional amounts of foreign exchange contracts in place that are designated and qualify as cash flow hedges totaled $265,640 and $611,488 at September 30, 2013 and December 31, 2012, respectively.
	The Company also enters into derivative contracts for forecasted product purchases and sales and for intercompany loans in foreign currencies that do not qualify for hedge accounting but are utilized for economic hedges as defined above. In these cases, the change in value of the economic hedge is recorded in the income statement and usually offsets the change in value recorded in the income statement for the underlying asset or liability. The notional amounts of economic hedges that do not qualify for hedge accounting totaled $1,380,878 and $1,574,667 at September 30, 2013 and December 31, 2012, respectively.
	Interest Rate Risk Management
	The Company enters into derivatives, particularly interest rate swaps and to a certain extent, interest rate options, to protect against the risk of rising interest rates. These interest rate derivatives are designated as cash flow hedges and have been entered into in order to effectively convert payments based on variable interest rates into payments at a fixed interest rate. The euro-denominated interest rate swaps expire in 2016 and have an interest rate of 1.73%. Interest payable and receivable under the swap agreements is accrued and recorded as an adjustment to interest expense.
	At September 30, 2013 and December 31, 2012, the notional amount of the euro-denominated interest rate swaps in place was €100,000 and €100,000 ($135,050 and $131,940 at September 30, 2013 and December 31, 2012, respectively).
	Derivative Financial Instruments Valuation
	The following table shows the carrying amounts of the Company's derivatives at September 30, 2013 and December 31, 2012.
				30-Sep-13						31-Dec-12
					Assets(2)			Liabilities(2)			Assets(2)			Liabilities(2)
	Derivatives in cash flow hedging relationships (1)
		Current
			Foreign exchange contracts		4,651			-2,117			7,839			-7,510
		Non-current
			Foreign exchange contracts		236			-785			942			-187
			Interest rate contracts		-			-4,374			-			-6,221
	Total			$	4,887		$	-7,276		$	8,781		$	-13,918
	Derivatives not designated as hedging instruments (1)
		Current
			Foreign exchange contracts		10,853			-4,048			23,396			-19,068
		Non-current
			Foreign exchange contracts		887			-901			132			-292
	Total			$	11,740		$	-4,949		$	23,528		$	-19,360
	(1) At September 30, 2013 and December 31, 2012, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP.
	(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date.
The carrying amounts for the current portion of derivatives indicated as assets in the table above are included in Prepaid expenses and other current assets in the Consolidated Balance Sheets while the current portion of those indicated as liabilities are included in Accrued expenses and other current liabilities. The non-current portions indicated as assets or liabilities are included in the Consolidated Balance Sheets in Other assets or Other liabilities, respectively.
The significant methods and assumptions used in estimating the fair values of derivative financial instruments are as follows:
The fair value of interest rate swaps is calculated by discounting the future cash flows on the basis of the market interest rates applicable for the remaining term of the contract at the balance sheet date. To determine the fair value of foreign exchange forward contracts, the contracted forward rate is compared to the current forward rate for the remaining term of the contract at the balance sheet date. The result is then discounted on the basis of the market interest rates prevailing at the balance sheet date for the applicable currency.
The Company includes its own credit risk for financial instruments deemed liabilities and counterparty-credit risks for financial instruments deemed assets when measuring the fair value of derivative financial instruments.
The Effect of Derivatives on the Consolidated Financial Statements
			Amount of Gain or (Loss) Recognized in OCI on Derivatives					Location of (Gain) or Loss Reclassified from AOCI in Income				Amount of (Gain) or Loss Reclassified from AOCI in Income
Derivatives in Cash Flow Hedging Relationships
			(Effective Portion) for the nine months ended September 30,										(Effective Portion) for the nine months ended September 30,
			2013			2012		(Effective Portion)				2013			2012
Interest rate contracts		$	-2,544		$	-12,040		Interest income/expense			$	20,476		$	17,014
Foreign exchange contracts			2,157			14,691		Costs of Revenue				-1,307			-5,000
Foreign exchange contracts								Interest income/expense				577			228
		$	-387		$	2,651					$	19,746		$	12,242
Derivatives not Designated as Hedging Instruments						Amount of (Gain) or Loss Recognized in Income on Derivatives for the nine months ended September 30,
			Location of (Gain) or Loss Recognized in Income on Derivative
						2013			2012
Foreign exchange contracts			Selling, general and administrative expense		$	-26,992		$	3,148
Foreign exchange contracts			Interest income/expense			5,690			4,940
					$	-21,302		$	8,088
For foreign exchange derivatives, the Company expects to recognize $1,680 of gains deferred in AOCI at September 30, 2013, in earnings during the next twelve months.
The Company expects to incur additional interest expense of $22,072 over the next twelve months which is currently deferred in AOCI. At September 30, 2013, this amount reflects the projected amortization of the settlement amount of the terminated swaps and the current fair value of the additional interest payments resulting from the remaining interest rate swap maturing in 2016.
At September 30, 2013, the Company had foreign exchange derivatives with maturities of up to 26 months and interest rate swaps with maturities of up to 37 months.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Commitments and Contingencies	'
	12. Commitments and Contingencies
	Legal and Regulatory Matters
	The Company is routinely involved in numerous claims, lawsuits, regulatory and tax audits, investigations and other legal matters arising, for the most part, in the ordinary course of its business of providing healthcare services and products. Legal matters that the Company currently deems to be material are described below. For the matters described below in which the Company believes a loss is both reasonably possible and estimable, an estimate of the loss or range of loss exposure is provided. For the other matters described below, the Company believes that the loss probability is remote and/or the loss or range of possible losses cannot be reasonably estimated at this time. The outcome of litigation and other legal matters is always difficult to predict accurately and outcomes that are not consistent with the Company's view of the merits can occur. The Company believes that it has valid defenses to the legal matters pending against it and is defending itself vigorously. Nevertheless, it is possible that the resolution of one or more of the legal matters currently pending or threatened could have a material adverse effect on its business, results of operations and financial condition.
	Commercial Litigation
	The Company was originally formed as a result of a series of transactions it completed pursuant to the Agreement and Plan of Reorganization dated as of February 4, 1996, by and between W.R. Grace & Co. and Fresenius SE (the "Merger"). At the time of the Merger, a W.R. Grace & Co. subsidiary known as W.R. Grace & Co.-Conn. had, and continues to have, significant liabilities arising out of product-liability related litigation (including asbestos-related actions), pre-Merger tax claims and other claims unrelated to National Medical Care, Inc. (“NMC”), which was W.R. Grace & Co.'s dialysis business prior to the Merger. In connection with the Merger, W.R. Grace & Co.-Conn. agreed to indemnify the Company, FMCH, and NMC against all liabilities of W.R. Grace & Co., whether relating to events occurring before or after the Merger, other than liabilities arising from or relating to NMC's operations. W.R. Grace & Co. and certain of its subsidiaries filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Grace Chapter 11 Proceedings”) on April 2, 2001.
	Prior to and after the commencement of the Grace Chapter 11 Proceedings, class action complaints were filed against W.R. Grace & Co. and FMCH by plaintiffs claiming to be creditors of W.R. Grace & Co.-Conn., and by the asbestos creditors' committees on behalf of the W.R. Grace & Co. bankruptcy estate in the Grace Chapter 11 Proceedings, alleging, among other things that the Merger was a fraudulent conveyance, violated the uniform fraudulent transfer act and constituted a conspiracy. All such cases have been stayed and transferred to or are pending before the U.S. District Court as part of the Grace Chapter 11 Proceedings.
	In 2003, the Company reached agreement with the asbestos creditors' committees on behalf of the W.R. Grace & Co. bankruptcy estate and W.R. Grace & Co. in the matters pending in the Grace Chapter 11 Proceedings for the settlement of all fraudulent conveyance and tax claims against it and other claims related to the Company that arise out of the bankruptcy of W.R. Grace & Co. Under the terms of the settlement agreement as amended (the “Settlement Agreement”), fraudulent conveyance and other claims raised on behalf of asbestos claimants will be dismissed with prejudice and the Company will receive protection against existing and potential future W.R. Grace & Co. related claims, including fraudulent conveyance and asbestos claims, and indemnification against income tax claims related to the non-NMC members of the W.R. Grace & Co. consolidated tax group upon confirmation of a W.R. Grace & Co. bankruptcy reorganization plan that contains such provisions. Under the Settlement Agreement, the Company will pay a total of $115,000 without interest, which has previously been accrued and is included on the Company's Consolidated Balance Sheets, to the W.R. Grace & Co. bankruptcy estate, or as otherwise directed by the Court, upon plan confirmation. No admission of liability has been or will be made. While the Company believes this accrual reasonably estimates its currently anticipated costs related to the continued defense and resolution of this matter, no assurances can be given that its actual costs incurred will not exceed the amount of this accrual. The Settlement Agreement has been approved by the U.S. District Court. In January and February 2011, the U.S. Bankruptcy Court entered orders confirming the plan of reorganization and the confirmation orders were affirmed by the U.S. District Court on January 31, 2012. Multiple parties have appealed to the Third Circuit Court of Appeals and the plan of reorganization will not be implemented until the appeals are finally resolved.
	Subsequent to the Merger, W.R. Grace & Co. was involved in a multi-step transaction involving Sealed Air Corporation (“Sealed Air,” formerly known as Grace Holding, Inc.). The Company is engaged in litigation with Sealed Air to confirm its entitlement to indemnification from Sealed Air for all losses and expenses incurred by the Company relating to pre-Merger tax liabilities and Merger-related claims. Under the Settlement Agreement, upon final confirmation of a plan of reorganization that satisfies the conditions of the Company's payment obligation, this litigation will be dismissed with prejudice.
	On April 4, 2003, FMCH filed a suit in the U. S. District Court for the Northern District of California, styled Fresenius USA, Inc., et al., v. Baxter International Inc., et al., Case No. C 03-1431, seeking a declaratory judgment that FMCH does not infringe patents held by Baxter International Inc. and its subsidiaries and affiliates (“Baxter”), that the patents are invalid, and that Baxter is without right or authority to threaten or maintain suit against FMCH for alleged infringement of Baxter's patents. In general, the asserted patents concern the use of touch screen interfaces for hemodialysis machines. Baxter filed counterclaims against FMCH seeking more than $140,000 in monetary damages and injunctive relief, and alleging that FMCH willfully infringed on Baxter's patents. On July 17, 2006, the court entered judgment on a jury verdict in favor of FMCH finding all asserted claims of Baxter patents invalid as obvious and/or anticipated in light of prior art.
	On February 13, 2007, the court granted Baxter's motion to set aside the jury's verdict in favor of FMCH and reinstated the patents and entered judgment of infringement. Following a trial on damages, the court entered judgment on November 6, 2007 in favor of Baxter on a jury award of $14,300. On April 4, 2008, the court denied Baxter's motion for a new trial, established a royalty payable to Baxter of 10% of the sales price for continuing sales of FMCH's 2008K hemodialysis machines and 7% of the sales price of related disposables, parts and service beginning November 7, 2007, and enjoined sales of the touchscreen-equipped 2008K machine effective January 1, 2009. The Company appealed the court's rulings to the United States Court of Appeals for the Federal Circuit (“Federal Circuit”). On September 10, 2009, the Federal Circuit reversed the district court's decision and determined that the asserted claims in two of the three patents at issue are invalid. As to the third patent, the Federal Circuit affirmed the district court's decision; however, the Court also vacated the injunction and award of damages. These issues were remanded to the District Court for reconsideration in light of the invalidity ruling on most of the claims. As a result, FMCH is no longer required to fund the court-approved escrow account set up to hold the royalty payments ordered by the district court. Funds of $70,000 were contributed to the escrow fund. Upon remand, the district court reduced the post-verdict damages award to $10,000 and $61,000 of the escrowed funds was returned to FMCH. In the parallel reexamination of the last surviving patent, the U.S. Patent and Trademark Office (“USPTO”) and the Board of Patent Appeals and Interferences ruled that the remaining Baxter patent is invalid. On May 17, 2012 the Federal Circuit affirmed the USPTO's ruling and invalidated the final remaining Baxter patent. The Federal Circuit issued a mandate to the USPTO to cancel the claims of the last remaining asserted Baxter HD patent. Baxter appealed to the Federal Circuit claiming that approximately $20,000 of damages awarded to it by the District Court before the Federal Circuit affirmed the USPTO ruling constitutes a final judgment that may be collected. On July 2, 2013, the Federal Circuit denied Baxter's appeal and ordered the District Court to dismiss the case. Baxter has requested a rehearing before the full Federal Circuit.
	On August 27, 2012, Baxter filed suit in the U.S. District Court for the Northern District of Illinois, styled Baxter International Inc., et al., v. Fresenius Medical Care Holdings, Inc., Case No. 12-cv-06890, alleging that the Company's LibertyTM cycler infringes certain U.S. patents that were issued to Baxter between October 2010 and June 2012. The Company believes it has valid defenses to these claims, and will defend this litigation vigorously.
	On April 5, 2013, the U.S. Judicial Panel on Multidistrict Litigation ordered that lawsuits filed in various federal courts alleging wrongful death and personal injury claims against FMCH and certain of its affiliates relating to FMCH's dialysate concentrate products NaturaLyte® and Granuflo® be transferred and consolidated for pretrial management purposes into a consolidated multidistrict litigation in the United States District Court for the District of Massachusetts, styled In Re: Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation, Case No. 2013-md-02428. These lawsuits allege generally that inadequate labeling and warnings for these products caused harm to patients. In addition, similar cases have been filed in several state courts that will not be formally consolidated with the federal multidistrict litigation. FMCH believes that these lawsuits are without merit, and will defend them vigorously.
	Other Litigation and Potential Exposures
	On February 15, 2011, a qui tam relator's complaint under the False Claims Act against FMCH was unsealed by order of the United States District Court for the District of Massachusetts and served by the relator. The United States has not intervened in the case United States ex rel. Chris Drennen v. Fresenius Medical Care Holdings, Inc., 2009 Civ. 10179 (D. Mass.). The relator's complaint, which was first filed under seal in February 2009, alleges that the Company seeks and receives reimbursement from government payors for serum ferritin and hepatitis B laboratory tests that are medically unnecessary or not properly ordered by a physician. On March 6, 2011, the United States Attorney for the District of Massachusetts issued a Civil Investigative Demand seeking the production of documents related to the same laboratory tests that are the subject of the relator's complaint. FMCH has cooperated fully in responding to the Civil Investigative Demand, and will vigorously contest the relator's complaint.
	On June 29, 2011, FMCH received a subpoena from the United States Attorney for the Eastern District of New York (“E.D.N.Y.”). On December 6, 2011, a single Company facility in New York received a subpoena from the Office of the Inspector General of the Department of Health and Human Services that was substantially similar to the one issued by the U.S. Attorney for the E.D.N.Y. These subpoenas are part of a criminal and civil investigation into relationships between retail pharmacies and outpatient dialysis facilities in the State of New York and into the reimbursement under government payor programs in New York for medications provided to patients with ESRD. Among the issues encompassed by the investigation is whether retail pharmacies may have provided or received compensation from the New York Medicaid program for pharmaceutical products that should be provided by the dialysis facilities in exchange for the New York Medicaid payment to the dialysis facilities. The Company has cooperated in the investigation.
	Civil investigative demands were issued under the supervision of the United States Attorneys for Rhode Island and Connecticut to American Access Care LLC (AAC) and certain affiliated entities prior to the Company's acquisition of AAC in October 2011. In March 2012, a third subpoena was issued under the supervision of the United States Attorney for the Southern District of Florida (Miami). In May 2013, a fourth subpoena was served by the United States Attorney for the Eastern District of Virginia (Richmond). Also in May 2013, updated document productions were requested by the US Attorneys for Rhode Island and Connecticut. Although the subpoenas cover a wide range of documents and activities of AAC, the focus of the investigation is procedure coding and related billing practices and procedures. As of October 18, 2013, a group of the prior owners of AAC assumed responsibility for responding to the subpoenas and committed to indemnify the Company pursuant to the terms of the acquisition agreement.
	The Company has received communications alleging certain conduct in certain countries outside the U.S. and Germany that may violate the U.S. Foreign Corrupt Practices Act (“FCPA”) or other anti-bribery laws. The Audit and Corporate Governance Committee of the Company's Supervisory Board is conducting an internal review with the assistance of independent counsel retained for such purpose. The Company voluntarily advised the U.S. Securities and Exchange Commission ( “SEC”) and the U.S. Department of Justice (“DOJ”) that allegations have been made and of the Company's internal review. The review has identified conduct that the Company has reported to the SEC and the DOJ. The Company's review and dialogue with the SEC and DOJ are ongoing. The Company cannot predict the final outcome of this matter.
	The Company's independent counsel, in conjunction with the Company's Compliance Department, have reviewed the Company's anti-corruption compliance program, including internal controls related to compliance with international anti-bribery laws, and appropriate enhancements are being implemented. The Company is fully committed to FCPA compliance.
	In December 2012 and January 2013, FMCH received subpoenas from the United States Attorneys for the District of Massachusetts and the Western District of Louisiana requesting production of a range of documents relating to products manufactured by FMCH, including the Granuflo® and Naturalyte® dialysate concentrate products. FMCH is cooperating fully in responding to these subpoenas.
	The Company filed claims for refunds contesting the Internal Revenue Service's (“IRS”) disallowance of FMCH's civil settlement payment deductions taken by FMCH in prior year tax returns. As a result of a settlement agreement with the IRS, the Company received a partial refund in September 2008 of $37,000, inclusive of interest and preserved its right to pursue claims in the United States Courts for refunds of all other disallowed deductions, which totaled approximately $126,000. On December 22, 2008, the Company filed a complaint for complete refund in the United States District Court for the District of Massachusetts, styled as Fresenius Medical Care Holdings, Inc. v. United States. On August 15, 2012, a jury entered a verdict for FMCH granting additional deductions of $95,000. On May 31, 2013, the District Court entered final judgment for FMCH in the amount of $50,400. On September 18, 2013, the IRS appealed the District Court's ruling to the United States Court of Appeals for the First Circuit (Boston).
	From time to time, the Company is a party to or may be threatened with other litigation or arbitration, claims or assessments arising in the ordinary course of its business. Management regularly analyzes current information including, as applicable, the Company's defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters.
	The Company, like other healthcare providers, conducts its operations under intense government regulation and scrutiny. It must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the marketing and distribution of such products, the operation of manufacturing facilities, laboratories and dialysis clinics, and environmental and occupational health and safety. With respect to its development, manufacture, marketing and distribution of medical products, if such compliance is not maintained, the Company could be subject to significant adverse regulatory actions by the FDA and comparable regulatory authorities outside the U.S. These regulatory actions could include warning letters or other enforcement notices from the FDA and/or comparable foreign regulatory authority, which may require the Company to expend significant time and resources in order to implement appropriate corrective actions. If the Company does not address matters raised in warning letters or other enforcement notices to the satisfaction of the FDA and/or comparable regulatory authorities outside the U.S., these regulatory authorities could take additional actions, including product recalls injunctions against the distribution of products or operation of manufacturing plants, civil penalties, seizures of the Company's products and/or criminal prosecution. The Company must also comply with the laws of the United States, including the federal Anti-Kickback Statute, the federal False Claims Act, the federal Stark Law and the federal Foreign Corrupt Practices Act as well as other federal and state fraud and abuse laws. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from the Company's interpretations or the manner in which it conducts its business. Enforcement has become a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence “qui tam” or “whistle blower” actions. In May 2009, the scope of the False Claims Act was expanded and additional protections for whistle blowers and procedural provisions to aid whistle blowers' ability to proceed in a False Claims Act case were added. By virtue of this regulatory environment, the Company's business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, investigative demands, subpoenas, other inquiries, claims and litigation relating to the Company's compliance with applicable laws and regulations. The Company may not always be aware that an inquiry or action has begun, particularly in the case of “whistle blower” actions, which are initially filed under court seal.
	The Company operates many facilities throughout the United States and other parts of the world. In such a decentralized system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies. The Company relies upon its management structure, regulatory and legal resources, and the effective operation of its compliance program to direct, manage and monitor the activities of these employees. On occasion, the Company may identify instances where employees or other agents deliberately, recklessly or inadvertently contravene the Company's policies or violate applicable law. The actions of such persons may subject the Company and its subsidiaries to liability under the Anti-Kickback Statute, the Stark Law, the False Claims Act and the Foreign Corrupt Practices Act, among other laws and comparable laws of other countries.
	Physicians, hospitals and other participants in the healthcare industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker's compensation or related claims, many of which involve large claims and significant defense costs. The Company has been and is currently subject to these suits due to the nature of its business and expects that those types of lawsuits may continue. Although the Company maintains insurance at a level which it believes to be prudent, it cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against the Company or any of its subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business.
	The Company has also had claims asserted against it and has had lawsuits filed against it relating to alleged patent infringements or businesses that it has acquired or divested. These claims and suits relate both to operation of the businesses and to the acquisition and divestiture transactions. The Company has, when appropriate, asserted its own claims, and claims for indemnification. A successful claim against the Company or any of its subsidiaries could have a material adverse effect upon its business, financial condition, and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business.

Business_Segment_Information

Business Segment Information	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Business Segment Information	'
	15. Business Segment and Corporate Information
	The Company has identified three operating segments, North America Segment, EMEALA and Asia-Pacific, which were determined based upon how the Company manages its businesses. All segments are primarily engaged in providing dialysis care services and the distribution of products and equipment for the treatment of ESRD. The Company has aggregated the EMEALA and the Asia-Pacific operating segments as the “International Segment.” The segments are aggregated due to their similar economic characteristics. These characteristics include same services provided and same products sold, the same type of patient population, similar methods of distribution of products and services and similar economic environments. The General Partner's management board member responsible for the profitability and cash flow of each segment's various businesses supervises the management of each operating segment. The accounting policies of the segments are the same as those the Company applies in preparing the consolidated financial statements under accounting principles generally accepted in the U.S. (“U.S. GAAP”).
	Management evaluates each segment using a measure that reflects all of the segment's controllable revenues and expenses. With respect to the performance of business operations, management believes that the most appropriate measure in this regard is operating income which measures the Company's source of earnings. The Company does not include the investment gain resulting from the 2012 Liberty Acquisition nor income taxes as it believes these items to be outside the segments' control. Financing is a corporate function, which the Company's segments do not control. Therefore, the Company does not include interest expense relating to financing as a segment measurement. Similarly, the Company does not allocate certain costs, which relate primarily to certain headquarters overhead charges, including accounting and finance, global research and development, etc. (“Corporate”), because the Company believes that these costs are also not within the control of the individual segments. Production of products, production asset management, quality management and procurement are centrally managed in Corporate by Global Manufacturing Operations. These corporate activities do not fulfill the definition of a segment. Products are transferred to the segments at cost; therefore no internal profit is generated. The associated internal revenues for the product transfers and their elimination are recorded as corporate activities. Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations. In addition, certain revenues, investments, and intangible assets, as well as any related expense, are not allocated to a segment but accounted for as Corporate.
	Information pertaining to the Company's segments and its Corporate activities for the three- and nine-months periods ended September 30, 2013 and 2012 is set forth below.
					North America Segment		International Segment		Segment Total		Corporate		Total
	Three months ended September 30, 2013
		Net revenue external customers		$	2,436,141	$	1,222,026	$	3,658,167	$	7,965	$	3,666,132
		Inter - segment revenue			2,591		-		2,591		-2,591		-
		Revenue			2,438,732		1,222,026		3,660,758		5,374		3,666,132
		Depreciation and amortization			-83,251		-45,824		-129,075		-35,204		-164,279
		Operating income			415,533		204,458		619,991		-62,731		557,260
		Income (loss) from equity method investees			3,965		-102		3,863		1,431		5,294
		Capital expenditures, acquisitions and investments			284,453		53,260		337,713		36,768		374,481
	Three months ended September 30, 2012
		Net revenue external customers		$	2,248,724	$	1,163,362	$	3,412,086	$	5,852	$	3,417,938
		Inter - segment revenue			2,501		-		2,501		-2,501		-
		Revenue			2,251,225		1,163,362		3,414,587		3,351		3,417,938
		Depreciation and amortization			-79,446		-43,942		-123,388		-28,824		-152,212
		Operating income			420,316		195,264		615,580		-47,938		567,642
		Income (loss) from equity method investees			6,642		53		6,695		-1,378		5,317
		Capital expenditures, acquisitions and investments			108,286		55,255		163,541		49,650		213,191
	Nine months ended September 30, 2013
		Net revenue external customers		$	7,098,638	$	3,619,000	$	10,717,638	$	24,930	$	10,742,568
		Inter - segment revenue			5,437		-		5,437		-5,437		-
		Revenue			7,104,075		3,619,000		10,723,075		19,493		10,742,568
		Depreciation and amortization			-244,619		-136,779		-381,398		-98,035		-479,433
		Operating Income			1,178,192		597,229		1,775,421		-180,609		1,594,812
		Income (loss) from equity method investees			11,899		866		12,765		1,753		14,518
		Segment assets			14,238,874		6,034,705		20,273,579		2,260,941		22,534,520
			thereof investments in equity method investees		256,195		387,565		643,760		-3,857		639,903
		Capital expenditures, acquisitions and investments(1)			504,733		202,137		706,870		103,062		809,932
	Nine months ended September 30, 2012
		Net revenue external customers		$	6,602,000	$	3,470,353	$	10,072,353	$	22,313	$	10,094,666
		Inter - segment revenue			9,041		-		9,041		-9,041		-
		Revenue			6,611,041		3,470,353		10,081,394		13,272		10,094,666
		Depreciation and amortization			-230,575		-129,784		-360,359		-86,104		-446,463
		Operating Income			1,199,234		597,399		1,796,633		-137,200		1,659,433
		Income (loss) from equity method investees			17,962		182		18,144		-3,472		14,672
		Segment assets			13,806,253		5,835,643		19,641,896		2,218,437		21,860,333
			thereof investments in equity method investees		257,324		369,943		627,267		-4,189		623,078
		Capital expenditures, acquisitions and investments(2)			1,970,330		155,075		2,125,405		113,388		2,238,793
		(1) International acquisitions exclude $8,403 of non-cash acquisitions for 2013.
		(2) North America acquisitions exclude $484,699 of non-cash acquisitions and International acquisitions exclude $4,720 of non-cash acquisitions for 2012.

Other_Comprehensive_Income

Other Comprehensive Income	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Other Comprehensive Income	'
	14. Other Comprehensive Income (Loss), net of tax
	Changes in accumulated other comprehensive income (loss), net of tax, by component for the nine months ended September 30, 2013 and 2012 are as follows:
			Gain (Loss) related to cash flow hedges			Actuarial gain (loss) on defined benefit pension plans			Gain (loss) related to foreign-currency translation		Total, before non-controlling interests		Non-controlling interests		Total
	Balance at December 31, 2011		$	-136,221		$	-111,215		$	-238,331	$	-485,767	$	3,048	$	-482,719
		Other comprehensive income (loss) before reclassifications		-18,150			-			31,550		13,400		1,241		14,641
		Amounts reclassified from accumulated other comprehensive income (loss) (1)		9,817			8,229			-		18,046		-		18,046
	Other comprehensive income (loss) after reclassifications			-8,333			8,229			31,550		31,446		1,241		32,687
	Balance at September 30, 2012		$	-144,554		$	-102,986		$	-206,781	$	-454,321	$	4,289	$	-450,032
	Balance at December 31, 2012		$	-138,341		$	-179,423		$	-174,349	$	-492,113	$	2,869	$	-489,244
		Other comprehensive income (loss) before reclassifications		124			-			-95,348		-95,224		-1,554		-96,778
		Amounts reclassified from accumulated other comprehensive income (loss) (1)		14,122			11,777			-		25,899		-		25,899
	Other comprehensive income (loss) after reclassifications			14,246			11,777			-95,348		-69,325		-1,554		-70,879
	Balance at September 30, 2013		$	-124,095		$	-167,646		$	-269,697	$	-561,438	$	1,315	$	-560,123
	(1) See separate table below for details about these reclassifications.
	Reclassifications out of accumulated other comprehensive income (loss) for the nine months ended September 30, 2013 and 2012 are as follows:
	Details about Accumulated Other Comprehensive Income (Loss) ("AOCI") Components			Amount of (Gain) Loss reclassified from AOCI in Income						Location of (Gain) Loss reclassified from AOCI in Income
				For the nine months ended September 30,
				2013			2012
	(Gain) Loss related to cash flow hedges
		Interest rate contracts		$	20,476		$	17,014		Interest income/expense
		Foreign exchange contracts			-1,307			-5,000		Costs of Revenue
		Foreign exchange contracts			577			228		Interest income/expense
					19,746			12,242		Total before tax
					-5,624			-2,425		Tax expense or benefit
				$	14,122		$	9,817		Net of tax
	Actuarial (Gain) Loss on defined benefit pension plans
		Amortization of unrealized (gain) /loss			19,095			13,537		-1
					19,095			13,537		Total before tax
					-7,318			-5,308		Tax expense or benefit
				$	11,777		$	8,229		Net of tax
	Total reclassifications for the period			$	25,899		$	18,046		Net of tax
	(1) Included in the computation of net periodic pension cost (see Note 9 for additional details).

Supplementary_Cash_Flow_Inform

Supplementary Cash Flow Information	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Cash Flow Supplemental Disclosures [Text Block]	'
	16. Supplementary Cash Flow Information
	The following additional information is provided with respect to the consolidated statements of cash flows:
			Nine months ended September 30,
			2013		2012
	Supplementary cash flow information:
		Cash paid for interest	$	337,143	$	316,734
		Cash paid for income taxes (1)	$	373,217	$	414,657
		Cash inflow for income taxes from stock option exercises	$	6,297	$	17,588
	Supplemental disclosures of cash flow information:
		Details for acquisitions:
		Assets acquired	$	-158,447	$	-2,434,645
		Liabilities assumed		19,923		282,789
		Noncontrolling interest subject to put provisions		16,317		86,729
		Noncontrolling interest		4,558		105,863
		Obligations assumed in connection with acquisition		8,403		4,720
		Cash paid		-109,246		-1,954,544
		Less cash acquired		5,471		171,795
		Net cash paid for acquisitions		-103,775		-1,782,749
		Cash paid for investments		-188,538		-386
		Cash paid for intangible assets		-5,143		-5,696
		Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets	$	-297,456	$	-1,788,831
		(1) Net of tax refund.

Supplemental_Condensed_Combini

Supplemental Condensed Combining Information	9 Months Ended
	Sep. 30, 2013
Notes to Consolidated Financial Statements [Abstract]	'
Supplemental Condensed Combining Information	'
	17. Supplemental Condensed Combining Information
	FMC Finance III, a former wholly-owned subsidiary of the Company, issued 6⅞% Senior Notes due 2017 in July 2007. On June 20, 2011, Fresenius Medical Care US Finance, Inc. (“US Finance”) acquired substantially all of the assets of FMC Finance III and assumed its obligations, including the 6⅞% Senior Notes and the related indenture. The 6⅞% senior notes are fully and unconditionally guaranteed, jointly and severally on a senior basis, by the Company and by D-GmbH and FMCH (“the Guarantor Subsidiaries”). The 6⅞% Senior Notes and related guarantees were issued in an exchange offer registered under the Securities Act of 1933. The financial statements in this report present the financial condition, results of operations and cash flows of the Company, on a consolidated basis at September 30, 2013 and December 31, 2012 and for the nine-months period ended September 30, 2013 and 2012. The following combining financial information for the Company is at September 30, 2013 and December 31, 2012 and for the nine-months periods ended September 30, 2013 and 2012, segregated between FMC US Finance as issuer, the Company, the Guarantor Subsidiaries, and the Company's other businesses (the “Non-Guarantor Subsidiaries”). For purposes of the condensed combining information, the Company and the Guarantor Subsidiaries carry their investments under the equity method. Other (income) expense includes income (loss) related to investments in consolidated subsidiaries recorded under the equity method for purposes of the condensed combining information. In addition, other (income) expense includes income and losses from profit and loss transfer agreements as well as dividends received.
			For the nine months ended September 30, 2013
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	1,525,867		$	-		$	11,646,195		$	-2,429,494		$	10,742,568
	Cost of revenue			-			-			1,009,678			-			8,699,457			-2,403,587			7,305,548
		Gross profit		-			-			516,189			-			2,946,738			-25,907			3,437,020
	Operating expenses (income):
		Selling, general and administrative(1)		-			69,946			156,445			-91,072			1,590,946			21,439			1,747,704
		Research and development		-			-			54,985			-			39,687			-168			94,504
	Operating (loss) income			-			-69,946			304,759			91,072			1,316,105			-47,178			1,594,812
	Other (income) expense:
		Interest, net		-5,144			149,956			5,767			131,973			27,900			-			310,452
		Other, net		-			-1,001,160			238,088			-593,924			-			1,356,996			-
	Income (loss) before income taxes			5,144			781,258			60,904			553,023			1,288,205			-1,404,174			1,284,360
		Income tax expense (benefit)		1,867			20,261			67,212			-16,135			464,200			-116,532			420,873
	Net Income (loss)			3,277			760,997			-6,308			569,158			824,005			-1,287,642			863,487
	Net Income attributable to noncontrolling interests			-			-			-			-			-			102,490			102,490
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	3,277		$	760,997		$	-6,308		$	569,158		$	824,005		$	-1,390,132		$	760,997
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
			For the nine months ended September 30, 2012
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	1,394,861		$	-		$	10,838,232		$	-2,138,427		$	10,094,666
	Cost of revenue			-			-			890,050			-			8,014,600			-2,118,678			6,785,972
		Gross profit		-			-			504,811			-			2,823,632			-19,749			3,308,694
	Operating expenses (income):
		Selling, general and administrative (1)		-			27,391			148,291			17,612			1,336,427			36,213			1,565,934
		Research and development		-			-			51,298			-			32,029			-			83,327
	Operating (loss) income			-			-27,391			305,222			-17,612			1,455,176			-55,962			1,659,433
	Other (income) expense:
		Investment gain		-			-			-			-			-139,600			-			-139,600
		Interest, net		-5,125			160,923			1,580			111,308			43,204			-850			311,040
		Other, net		-			-1,175,959			201,306			-723,885			-			1,698,538			-
	Income (loss) before income taxes			5,125			987,645			102,336			594,965			1,551,572			-1,753,650			1,487,993
		Income tax expense (benefit)		1,877			57,948			88,213			-50,859			555,710			-190,535			462,354
	Net Income (loss)			3,248			929,697			14,123			645,824			995,862			-1,563,115			1,025,639
	Net Income attributable to noncontrolling interests			-			-			-			-			-			95,942			95,942
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	3,248		$	929,697		$	14,123		$	645,824		$	995,862		$	-1,659,057		$	929,697
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
				For the nine months ended September 30, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	3,277		$	760,997		$	-6,308		$	569,158		$	824,005		$	-1,287,642		$	863,487
		Gain (loss) related to cash flow hedges			-			17,880			-			-			1,479			-			19,359
		Actuarial gain (loss) on defined benefit pension plans			-			97			1,906			16,926			166			-			19,095
		Gain (loss) related to foreign currency translation			-			-83,209			17,734			-			-37,229			5,802			-96,902
		Income tax (expense) benefit related to components of other comprehensive income			-			-5,172			-556			-6,677			-26			-			-12,431
	Other comprehensive income (loss), net of tax				-			-70,404			19,084			10,249			-35,610			5,802			-70,879
	Total comprehensive income			$	3,277		$	690,593		$	12,776		$	579,407		$	788,395		$	-1,281,840		$	792,608
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			100,936			100,936
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	3,277		$	690,593		$	12,776		$	579,407		$	788,395		$	-1,382,776		$	691,672
				For the nine months ended September 30, 2012
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	3,248		$	929,697		$	14,123		$	645,824		$	995,862		$	-1,563,115		$	1,025,639
		Gain (loss) related to cash flow hedges			-			-6,629			-9			11,725			9,806			-			14,893
		Actuarial gain (loss) on defined benefit pension plans			-			22			276			13,229			10			-			13,537
		Gain (loss) related to foreign currency translation			-			-14,402			2			-			49,371			-2,180			32,791
		Income tax (expense) benefit related to components of other comprehensive income			-			3,629			-76			-9,845			-22,242			-			-28,534
	Other comprehensive income (loss), net of tax				-			-17,380			193			15,109			36,945			-2,180			32,687
	Total comprehensive income			$	3,248		$	912,317		$	14,316		$	660,933		$	1,032,807		$	-1,565,295		$	1,058,326
	Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			97,183			97,183
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	3,248		$	912,317		$	14,316		$	660,933		$	1,032,807		$	-1,662,478		$	961,143
			At September 30, 2013
			Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
Current assets:
	Cash and cash equivalents		$	36		$	65		$	3,939		$	-		$	598,115		$	-		$	602,155
	Trade accounts receivable, less allowance for doubtful accounts			-			-			148,801			-			2,852,896			203			3,001,900
	Accounts receivable from related parties			1,252,224			1,936,651			1,134,433			1,638,081			4,651,538			-10,471,655			141,272
	Inventories			-			-			280,719			-			913,073			-140,437			1,053,355
	Prepaid expenses and other current assets			-			71,670			49,271			17			825,766			820			947,544
	Deferred taxes			-			-			-			-			295,581			2,368			297,949
		Total current assets		1,252,260			2,008,386			1,617,163			1,638,098			10,136,969			-10,608,701			6,044,175
Property, plant and equipment, net				-			692			228,568			-			2,902,301			-123,657			3,007,904
Intangible assets				-			609			74,649			-			596,216			-72			671,402
Goodwill				-			-			56,664			-			11,464,148			-			11,520,812
Deferred taxes				-			74,649			7,522			-			124,386			-65,269			141,288
Other assets and notes receivables(1)				-			13,084,810			28,184			12,194,966			5,348,178			-29,507,199			1,148,939
	Total assets		$	1,252,260		$	15,169,146		$	2,012,750		$	13,833,064		$	30,572,198		$	-40,304,898		$	22,534,520
Current liabilities:
	Accounts payable		$	-		$	285		$	29,090		$	-		$	476,030		$	-		$	505,405
	Accounts payable to related parties			-			2,231,722			816,334			1,569,192			6,028,772			-10,535,768			110,252
	Accrued expenses and other current liabilities			11,833			29,192			140,393			9,688			1,688,889			8,534			1,888,529
	Short-term borrowings			-			27			-			-			112,462			-			112,489
	Short-term borrowings from related parties			-			-			-			-			73,048			-			73,048
	Current portion of long-term debt and capital lease obligations			-			239,766			-			200,000			31,795			-			471,561
	Income tax payable			-			127,094			-			-			59,869			8,176			195,139
	Deferred taxes			-			3,001			7,546			-			64,397			-41,330			33,614
		Total current liabilities		11,833			2,631,087			993,363			1,778,880			8,535,262			-10,560,388			3,390,037
Long term debt and capital lease obligations, less current portion				1,168,699			349,929			-			2,399,094			6,933,357			-3,078,776			7,772,303
Long term borrowings from related parties				-			3,289,494			-			2,057,898			7,236			-5,354,628			-
Other liabilities				-			5,600			14,629			-			250,842			31,684			302,755
Pension liabilities				-			10,661			219,439			-			244,756			-			474,856
Income tax payable				3,260			27,850			-			-			41,332			120,990			193,432
Deferred taxes				-			-			-			-			692,077			-29,450			662,627
		Total liabilities		1,183,792			6,314,621			1,227,431			6,235,872			16,704,862			-18,870,568			12,796,010
Noncontrolling interests subject to put provisions				-			-			0			-			641,021			-			641,021
Total FMC-AG & Co. KGaA shareholders' equity				68,468			8,854,525			785,319			7,597,192			12,983,351			-21,434,330			8,854,525
Noncontrolling interests not subject to put provisions				-			-			-			-			242,964			-			242,964
Total equity				68,468			8,854,525			785,319			7,597,192			13,226,315			-21,434,330			9,097,489
	Total liabilities and equity		$	1,252,260		$	15,169,146		$	2,012,750		$	13,833,064		$	30,572,198		$	-40,304,898		$	22,534,520
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
			At December 31, 2012
			Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
Current assets:
	Cash and cash equivalents		$	1		$	78		$	501		$	-		$	686,457		$	1,003		$	688,040
	Trade accounts receivable, less allowance for doubtful accounts			-			-			170,627			-			2,848,797			-			3,019,424
	Accounts receivable from related parties			1,269,471			2,257,445			1,449,317			3,562,953			4,398,630			-12,800,007			137,809
	Inventories			-			-			271,039			-			885,613			-119,843			1,036,809
	Prepaid expenses and other current assets			-			72,022			27,693			167			837,152			727			937,761
	Deferred taxes			-			-			-			-			311,280			-3,667			307,613
		Total current assets		1,269,472			2,329,545			1,919,177			3,563,120			9,967,929			-12,921,787			6,127,456
Property, plant and equipment, net				-			611			206,873			-			2,856,000			-122,881			2,940,603
Intangible assets				-			584			67,874			-			641,714			-56			710,116
Goodwill				-			-			54,848			-			11,367,041			-			11,421,889
Deferred taxes				-			51,111			10,123			-			131,452			-58,933			133,753
Other assets and notes receivables (1)				-			12,675,998			650,255			11,766,104			-4,751,531			-19,348,645			992,181
	Total assets		$	1,269,472		$	15,057,849		$	2,909,150		$	15,329,224		$	20,212,605		$	-32,452,302		$	22,325,998
Current liabilities:
	Accounts payable		$	-		$	1,935		$	41,114		$	-		$	579,245		$	-		$	622,294
	Accounts payable to related parties			-			2,234,205			491,525			1,598,852			8,663,240			-12,864,472			123,350
	Accrued expenses and other current liabilities			29,771			27,530			102,728			3,157			1,611,997			12,288			1,787,471
	Short-term borrowings			-			38			-			-			117,812			-			117,850
	Short-term borrowings from related parties			-			-			-			-			3,973			-			3,973
	Current portion of long-term debt and capital lease obligations			-			207,160			-			100,000			27,587			-			334,747
	Income tax payable			-			130,636			-			-			19,367			-			150,003
	Deferred taxes			-			1,622			8,126			-			61,774			-41,219			30,303
		Total current liabilities		29,771			2,603,126			643,493			1,702,009			11,084,995			-12,893,403			3,169,991
Long term debt and capital lease obligations, less current portion				1,172,397			285,049			-			2,559,340			7,020,190			-3,251,236			7,785,740
Long term borrowings from related parties				-			3,212,455			657,284			2,019,925			64,530			-5,898,020			56,174
Other liabilities				-			6,696			12,679			110,637			96,322			33,923			260,257
Pension liabilities				-			7,753			202,219			-			247,701			-			457,673
Income tax payable				2,113			264			-			-			52,684			146,581			201,642
Deferred taxes				-			-			-			-			685,158			-21,157			664,001
		Total liabilities		1,204,281			6,115,343			1,515,675			6,391,911			19,251,580			-21,883,312			12,595,478
Noncontrolling interests subject to put provisions				-			-			-			-			523,260			-			523,260
Total FMC-AG & Co. KGaA shareholders' equity				65,191			8,942,506			1,393,475			8,937,313			173,011			-10,568,990			8,942,506
Noncontrolling interests not subject to put provisions				-			-			-			-			264,754			-			264,754
Total equity				65,191			8,942,506			1,393,475			8,937,313			437,765			-10,568,990			9,207,260
	Total liabilities and equity		$	1,269,472		$	15,057,849		$	2,909,150		$	15,329,224		$	20,212,605		$	-32,452,302		$	22,325,998
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
				For the nine months ended September 30, 2013
				Issuer			Guarantors
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH		Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
Operating Activities:
	Net income (loss)			$	3,277		$	760,997		$	-6,308		$	569,158		$	824,005		$	-1,287,642		$	863,487
	Adjustments to reconcile net income to net cash provided by (used in) operating activities:
	Equity affiliate income				-			-547,834			-			-593,924			-			1,141,758			-
		Depreciation and amortization			-			512			38,203			-			465,002			-24,284			479,433
		Change in deferred taxes, net			-			-27,091			1,372			-			25,028			-13,513			-14,204
		(Gain) loss on sale of fixed assets and investments			-			-12			-304			-			-6,086			-			-6,402
		(Gain) loss on investments			-			-			-66			-			-			66			-
		Compensation expense related to stock options			-			18,484			-			-			-			-			18,484
		Cash inflow (outflow) from hedging			-			-4,040			-			-			-			-			-4,040
		Investments in equity method investees, net			-			22,755			-			-			-11,965			-			10,790
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			-			-			17,616			-			-32,888			-198			-15,470
		Inventories			-			-			-3,210			-			-41,613			24,714			-20,109
		Prepaid expenses and other current and non-current assets			-			17,451			-18,106			-87,639			144,519			-1,061			55,164
		Accounts receivable from / payable to related parties			19,612			-127,112			93,191			98,809			-202,653			101,988			-16,165
		Accounts payable, accrued expenses and other current and non-current liabilities			-17,939			14,143			37,724			6,531			41,288			-3,004			78,743
		Income tax payable			1,147			20,440			-			-16,135			3,837			7,020			16,309
			Net cash provided by (used in) operating activities		6,097			148,693			160,112			-23,200			1,208,474			-54,156			1,446,020
Investing Activities:
	Purchases of property, plant and equipment				-			-235			-56,354			-			-483,424			27,537			-512,476
	Proceeds from sale of property, plant and equipment				-			17			468			-			18,098			-			18,583
	Disbursement of loans to related parties				-			487,243			-			165,814			-			-653,057			-
	Acquisitions and investments, net of cash acquired, and purchases of intangible assets				-			-32,060			-4,670			-1,000			-292,784			33,058			-297,456
	Proceeds from divestitures				-			-			-			-			17,984			-			17,984
			Net cash provided by (used in) investing activities		-			454,965			-60,556			164,814			-740,126			-592,462			-773,365
Financing Activities:
	Short-term borrowings, net				-			12,237			-96,214			-			94,366			-			10,389
	Long-term debt and capital lease obligations, net				-6,062			83,515			-			1,590,348			-2,309,633			653,057			11,225
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			37,000			-			37,000
	Proceeds from exercise of stock options				-			68,577			-			-			6,298			-			74,875
	Proceeds from conversion of preference shares into ordinary shares				-			34,784			-			-			-			-			34,784
	Purchase of treasury stock				-			-505,014			-			-			-			-			-505,014
	Dividends paid				-			-296,134			-			-			-2,861			2,861			-296,134
	Capital increase (decrease)				-			-			-			-1,731,962			1,742,265			-10,303			-
	Distributions to noncontrolling interest				-			-			-			-			-162,239			-			-162,239
	Contributions from noncontrolling interest				-			-			-			-			52,357			-			52,357
			Net cash provided by (used in) financing activities		-6,062			-602,035			-96,214			-141,614			-542,447			645,615			-742,757
Effect of exchange rate changes on cash and cash equivalents					-			-1,636			96			-			-14,243			-			-15,783
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					35			-13			3,438			-			-88,342			-1,003			-85,885
Cash and cash equivalents at beginning of period					1			78			501			-			686,457			1,003			688,040
Cash and cash equivalents at end of period				$	36		$	65		$	3,939		$	-		$	598,115		$	-		$	602,155
				For the nine months ended September 30, 2012
				Issuer			Guarantors									Non-Guarantor Subsidiaries
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH						Combining Adjustment				Combined Total
Operating Activities:
	Net income (loss)			$	3,248		$	929,697		$	14,123		$	645,824		$	995,862		$	-1,563,115		$	1,025,639
	Adjustments to reconcile net income to net cash provided by (used in) operating activities:
	Equity affiliate income				-			-751,747			-			-723,885			-			1,475,632			-
		Depreciation and amortization			-			356			34,877			-			432,726			-21,496			446,463
		Change in deferred taxes, net			-			9,518			5,757			-			61,782			-5,669			71,388
		(Gain) loss on sale of fixed assets and investments			-			-39			-109			-			-31,674			-			-31,822
		Investment (gain)			-			-			-			-			-139,600			-			-139,600
		Compensation expense related to stock options			-			19,685			-			-			-			-			19,685
		Cash inflow (outflow) from hedging			-			1,318			-			-			-15,221			-			-13,903
		Investments in equity method investees, net			-			36,339			-			-			-11,256			-			25,083
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			-			-			-22,199			-			19,309			-			-2,890
		Inventories			-			-			-36,526			-			-19,777			13,089			-43,214
		Prepaid expenses and other current and non-current assets			-			136,300			-20,822			25,710			3,468			68			144,724
		Accounts receivable from / payable to related parties			5,230			-325,366			60,662			84,245			104,633			60,572			-10,024
		Accounts payable, accrued expenses and other current and non-current liabilities			-7,273			9,271			45,374			894			12,220			-1,466			59,020
		Income tax payable			106			-9,813			-			-50,859			1,257			-23,866			-83,175
			Net cash provided by (used in) operating activities		1,311			55,519			81,137			-18,071			1,413,729			-66,251			1,467,374
Investing Activities:
	Purchases of property, plant and equipment				-			-399			-58,818			-			-420,367			29,622			-449,962
	Proceeds from sale of property, plant and equipment				-			39			288			-			10,965			-			11,292
	Disbursement of loans to related parties				-			-28,315			90			960,074			-			-931,849			-
	Acquisitions and investments, net of cash acquired, and net purchases of intangible assets				-			-1,613,292			-1,138			-			-1,787,208			1,612,807			-1,788,831
	Proceeds from divestitures				-			44			-			-			231,747			-44			231,747
			Net cash provided by (used in) investing activities		-			-1,641,923			-59,578			960,074			-1,964,863			710,536			-1,995,754
Financing Activities:
	Short-term borrowings, net				-			26,118			-21,516			-			67,723			-			72,325
	Long-term debt and capital lease obligations, net				-1,312			1,751,969			-			-942,003			-844,418			931,849			896,085
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			12,500			-			12,500
	Proceeds from exercise of stock options				-			76,950			-			-			17,589			-			94,539
	Dividends paid				-			-271,733			-			-			-240			240			-271,733
	Capital increase (decrease)				-			-			-			-			1,576,424			-1,576,424			-
	Distributions to noncontrolling interest				-			-			-			-			-131,783			-			-131,783
	Contributions from noncontrolling interest				-			-			-			-			15,167			-			15,167
			Net cash provided by (used in) financing activities		-1,312			1,583,304			-21,516			-942,003			712,962			-644,335			687,100
Effect of exchange rate changes on cash and cash equivalents					-			5,853			-			-			-2,814			-			3,039
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					-1			2,753			43			-			159,014			-50			161,759
Cash and cash equivalents at beginning of period					1			2			144			-			457,145			-			457,292
Cash and cash equivalents at end of period				$	0		$	2,755		$	187		$	-		$	616,159		$	-50		$	619,051

Acquisition_of_Liberty_Dialysi2

Acquisition of Liberty Dialysis Holdings (Tables)	9 Months Ended
	Sep. 30, 2013
Business Acquisition, Date of Acquisition [Abstract]	'
Acquisition [Text Block]	'
	Assets held for sale		$	164,068
	Trade accounts receivable			149,219
	Other current assets			17,458
	Deferred tax assets			14,932
	Property, plant and equipment			168,335
	Intangible assets and other assets			84,556
	Goodwill			2,003,465
	Accounts payable, accrued expenses and other current liabilities			-105,403
	Income tax payable and deferred taxes			-33,597
	Short-term borrowings, other financial liabilities, long-term debt and capital lease obligations			-72,101
	Other liabilities			-39,923
	Noncontrolling interests (subject and not subject to put provisions)			-169,651
	Total acquisition cost		$	2,181,358
	Less non-cash contributions at fair value
		Investment at acquisition date		-201,915
		Long-term Notes Receivable		-282,784
	Total non-cash items		$	-484,699
	Net Cash paid		$	1,696,659

Acquisition_of_Liberty_Dialysi3

Acquisition of Liberty Dialysis Holdings - Pro Forma (Tables)	9 Months Ended
	Sep. 30, 2013
Pro Forma (Tables) [Abstract]	'
Pro Forma Tabular Disclosures [Table Text Block]	'
			For the three months ended September 30,		For the nine months ended September 30,
			2012			2012
	Net revenue		$	3,415,472	$	10,197,670
	Net income attributable to shareholders of FMC-AG & Co. KGaA			268,467		797,867
	Income per ordinary share
		Basic	$	0.88	$	2.62
		Fully diluted	$	0.87	$	2.6

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventories (Tables) [Abstract]	'
Inventory Disclosure Tables [Text Block]	'
				30-Sep-13		31-Dec-12
	Finished goods		$	646,659	$	627,338
	Raw materials and purchased components			192,352		171,373
	Health care supplies			127,715		154,840
	Work in process			86,629		83,258
		Inventories	$	1,053,355	$	1,036,809

Longterm_Debt_and_Capital_Leas1

Long-term Debt and Capital Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2013
Long Term Debt and Capital Lease Obligations (Tables) [Abstract]	'
Schedule of long-term debt	'
		30-Sep-13		31-Dec-12
	2012 Credit Agreement	$	2,869,194	$	2,659,340
	Senior Notes		4,786,706		4,743,442
	Euro Notes		45,579		51,951
	European Investment Bank Agreements		189,070		324,334
	Accounts receivable facility		199,000		162,000
	Capital lease obligations		23,171		15,618
	Other		131,144		163,802
	Long-term debt and capital lease obligations		8,243,864		8,120,487
	Less current maturities		-471,561		-334,747
	Long-term debt and capital lease obligations, less current portion		7,772,303		7,785,740
	Long-term debt from related parties		-		56,174
	Long-term debt and capital lease obligations and long-term debt from related parties	$	7,772,303	$	7,841,914
2006 Senior Credit Agreement Table	'
		Maximum Amount Available September 30, 2013				Balance Outstanding September 30, 2013
	Revolving Credit USD	$	600,000	$	600,000	$	49,094	$	49,094
	Revolving Credit EUR	€	500,000	$	675,250	€	200,000	$	270,100
	Term Loan A	$	2,550,000	$	2,550,000	$	2,550,000	$	2,550,000
				$	3,825,250			$	2,869,194
		Maximum Amount Available December 31, 2012				Balance Outstanding December 31, 2012
	Revolving Credit USD	$	600,000	$	600,000	$	59,340	$	59,340
	Revolving Credit EUR	€	500,000	$	659,700	€	-	$	-
	Term Loan A	$	2,600,000	$	2,600,000	$	2,600,000	$	2,600,000
				$	3,859,700			$	2,659,340

Earning_Per_Share_Tables

Earning Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share (Tables) [Abstract]	'
Schedule of Earning per Share	'
			For the three months ended September 30,					For the nine months ended September 30,
			2013		2012			2013			2012
	Numerators:
	Net income attributable to shareholders of FMC-AG & Co. KGaA		$	272,974	$	269,862		$	760,997		$	929,697
	less:
		Dividend preference on Preference shares		-		25			-			76
	Income available to all classes of shares		$	272,974	$	269,837		$	760,997		$	929,621
	Denominators:
	Weighted average number of:
	Ordinary shares outstanding			301,310,149		301,531,173			302,158,886			300,720,312
	Preference shares outstanding			-		3,971,607			2,590,857			3,968,082
	Total weighted average shares outstanding			301,310,149		305,502,780			304,749,743			304,688,394
	Potentially dilutive Ordinary shares			445,648		2,008,318			637,188			1,740,599
	Potentially dilutive Preference shares			-		17,392			-			17,209
	Total weighted average Ordinary shares outstanding assuming dilution			301,755,797		303,539,491			302,796,074			302,460,911
	Total weighted average Preference shares outstanding assuming dilution			-		3,988,999			2,590,857			3,985,291
	Basic income per Ordinary share		$	0.91	$	0.88		$	2.5		$	3.05
	Fully diluted income per Ordinary share		$	0.9	$	0.88		$	2.49		$	3.03
	Period		Average price paid per share		Average price paid per share(1)		Total number of shares purchased as part of publicly announced plans or programs			Total Value of Shares Repurchased(4)			Total Value of Shares Repurchased(2), (4)			Maximum value of shares that may yet be purchased under plans or programs as of the end of the period(3)
				in €		in $					in €			in $		in €		in $
											in thousands
	May-13		€	52.96	$	68.48		1,078,255		€	57,107		$	73,842	€	327,893	$	426,458
	Jun-13		€	53.05	$	69.95		2,502,552		€	132,769		$	175,047	€	195,124	$	255,222
	Jul-13		€	49.42	$	64.63		2,972,770		€	146,916		$	192,124	€	48,208	$	63,996
	Aug-13		€	48.4	$	64.3		995,374		€	48,174		$	64,001	€	-	$	-
	Total		€	51	$	66.9		7,548,951		€	384,966		$	505,014
	(1) The dollar value is calculated using the daily exchange rate for the share repurchases made during the month.
	(2) The value of the shares repurchased in Dollar is calculated using the total value of the shares purchased in Euro converted using the daily exchange rate for the transactions.
	(3) The maximum Dollar value of the shares remaining is calculated using the maximum Euro value of shares that may yet be repurchased converted at the end of the month spot rate.
	(4) This amount is inclusive of fees (net of taxes) paid in the amount of approximately $106 (€ 81) for services rendered.

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2013
Employee Benefit Plans (Tables) [Abstract]	'
Schedule of the components of net periodic benefit cost	'
		Three months ended September 30,				Nine months ended September 30,
		2013		2012		2013		2012
	Components of net periodic benefit cost:
	Service cost	$	3,932	$	2,645	$	11,601	$	7,982
	Interest cost		6,635		6,590		20,130		19,528
	Expected return on plan assets		-3,415		-3,796		-10,215		-11,446
	Amortization of unrealized losses		6,318		4,794		19,095		13,537
	Net periodic benefit costs	$	13,470	$	10,233	$	40,611	$	29,601

Noncontrolling_Interests_Subje1

Noncontrolling Interests Subject To Put Provisions (Tables)	9 Months Ended
	Sep. 30, 2013
Noncontrolling Interests Subject To Put Provisions (Tables) [Abstract]	'
Noncontrolling Interests Subject to Put Provisions	'
	10. Noncontrolling Interests Subject to Put Provisions
	The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, the development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions.
	At September 30, 2013 and December 31, 2012, the Company's potential obligations under these put options were $641,021 and $523,260, respectively, of which, at September 30, 2013, put options with an aggregate purchase obligation of $252,319 were exercisable. One put option was exercised for a total consideration of $3,100 during the first nine months of 2013.
	Following is a roll forward of noncontrolling interests subject to put provisions for the nine months ended September 30, 2013 and the year ended December 31, 2012:
		30-Sep-13		31-Dec-12
	Beginning balance as of January 1,	$	523,260	$	410,491
	Contributions to noncontrolling interests		-88,847		-114,536
	Purchase/ sale of noncontrolling interests		8,556		134,643
	Contributions from noncontrolling interests		14,626		16,565
	Changes in fair value of noncontrolling interests		105,389		-18,880
	Net income		77,467		94,718
	Other comprehensive income (loss)		570		259
	Ending balance as of September 30, 2013 and December 31, 2012	$	641,021	$	523,260

Patient_Service_Revenue_Tables

Patient Service Revenue (Tables)	9 Months Ended
	Sep. 30, 2013
Patient Service Revenue by Payor (Abstract)	'
Patient Service Revenue [Text Block]	'
		For the nine months ended September 30,
			2013		2012
	Medicare ESRD program	$	3,258,043	$	2,955,411
	Private/alternative payors		2,833,762		2,671,895
	Medicaid and other government sources		288,878		287,726
	Hospitals		309,164		299,067
	Total patient service revenue	$	6,689,847	$	6,214,099

Financial_Instrument_Tables

Financial Instrument (Tables)	9 Months Ended
	Sep. 30, 2013
Financial Instruments (Tables) [Abstract]	'
Non-Derivative Financial Instruments	'
						September 30,						December 31,
						2013						2012
			Fair Value			Carrying			Fair			Carrying			Fair
			Hierarchy			Amount			Value			Amount			Value
	Assets
		Cash and cash equivalents	1		$	602,155			602,155		$	688,040			688,040
		Accounts Receivable(1)	2			3,143,172			3,143,172			3,157,233			3,157,233
		Long-term Notes Receivable	3			165,648			172,244			-			-
	Liabilities
		Accounts payable(1)	2			615,657			615,657			745,644			745,644
		Short-term borrowings(1)	2			185,537			185,537			121,823			121,823
		Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes	2			542,385			542,385			721,928			721,928
		2012 Credit Agreement	2			2,869,194			2,859,632			2,659,340			2,652,840
		Senior Notes	2			4,786,706			5,160,957			4,743,442			5,296,325
		Euro Notes	2			45,579			46,236			51,951			54,574
	Noncontrolling interests subject to put provisions		3			641,021			641,021			523,260			523,260
	(1) Also includes amounts from related parties.
Derivative Financial Instruments Valuation	'
				30-Sep-13						31-Dec-12
					Assets(2)			Liabilities(2)			Assets(2)			Liabilities(2)
	Derivatives in cash flow hedging relationships (1)
		Current
			Foreign exchange contracts		4,651			-2,117			7,839			-7,510
		Non-current
			Foreign exchange contracts		236			-785			942			-187
			Interest rate contracts		-			-4,374			-			-6,221
	Total			$	4,887		$	-7,276		$	8,781		$	-13,918
	Derivatives not designated as hedging instruments (1)
		Current
			Foreign exchange contracts		10,853			-4,048			23,396			-19,068
		Non-current
			Foreign exchange contracts		887			-901			132			-292
	Total			$	11,740		$	-4,949		$	23,528		$	-19,360
	(1) At September 30, 2013 and December 31, 2012, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP.
	(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date.
Effect of Derivatives on the Consolidated Financial Statements	'
	The Effect of Derivatives on the Consolidated Financial Statements
				Amount of Gain or (Loss) Recognized in OCI on Derivatives					Location of (Gain) or Loss Reclassified from AOCI in Income				Amount of (Gain) or Loss Reclassified from AOCI in Income
	Derivatives in Cash Flow Hedging Relationships
				(Effective Portion) for the nine months ended September 30,										(Effective Portion) for the nine months ended September 30,
				2013			2012		(Effective Portion)				2013			2012
	Interest rate contracts		$	-2,544		$	-12,040		Interest income/expense			$	20,476		$	17,014
	Foreign exchange contracts			2,157			14,691		Costs of Revenue				-1,307			-5,000
	Foreign exchange contracts								Interest income/expense				577			228
			$	-387		$	2,651					$	19,746		$	12,242
	Derivatives not Designated as Hedging Instruments						Amount of (Gain) or Loss Recognized in Income on Derivatives for the nine months ended September 30,
				Location of (Gain) or Loss Recognized in Income on Derivative
							2013			2012
	Foreign exchange contracts			Selling, general and administrative expense		$	-26,992		$	3,148
	Foreign exchange contracts			Interest income/expense			5,690			4,940
						$	-21,302		$	8,088

Other_Comprehensive_Income_Tab

Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2013
Other Comprehensive Income (Tables) [Abstract]	'
Other Comprehensive Income Rollforward [Text Block]	'
			Gain (Loss) related to cash flow hedges			Actuarial gain (loss) on defined benefit pension plans			Gain (loss) related to foreign-currency translation		Total, before non-controlling interests		Non-controlling interests		Total
	Balance at December 31, 2011		$	-136,221		$	-111,215		$	-238,331	$	-485,767	$	3,048	$	-482,719
		Other comprehensive income (loss) before reclassifications		-18,150			-			31,550		13,400		1,241		14,641
		Amounts reclassified from accumulated other comprehensive income (loss) (1)		9,817			8,229			-		18,046		-		18,046
	Other comprehensive income (loss) after reclassifications			-8,333			8,229			31,550		31,446		1,241		32,687
	Balance at September 30, 2012		$	-144,554		$	-102,986		$	-206,781	$	-454,321	$	4,289	$	-450,032
	Balance at December 31, 2012		$	-138,341		$	-179,423		$	-174,349	$	-492,113	$	2,869	$	-489,244
		Other comprehensive income (loss) before reclassifications		124			-			-95,348		-95,224		-1,554		-96,778
		Amounts reclassified from accumulated other comprehensive income (loss) (1)		14,122			11,777			-		25,899		-		25,899
	Other comprehensive income (loss) after reclassifications			14,246			11,777			-95,348		-69,325		-1,554		-70,879
	Balance at September 30, 2013		$	-124,095		$	-167,646		$	-269,697	$	-561,438	$	1,315	$	-560,123
	(1) See separate table below for details about these reclassifications.
Other Comprehensive Income Reclassifications [Text Block]	'
	Details about Accumulated Other Comprehensive Income (Loss) ("AOCI") Components			Amount of (Gain) Loss reclassified from AOCI in Income						Location of (Gain) Loss reclassified from AOCI in Income
				For the nine months ended September 30,
				2013			2012
	(Gain) Loss related to cash flow hedges
		Interest rate contracts		$	20,476		$	17,014		Interest income/expense
		Foreign exchange contracts			-1,307			-5,000		Costs of Revenue
		Foreign exchange contracts			577			228		Interest income/expense
					19,746			12,242		Total before tax
					-5,624			-2,425		Tax expense or benefit
				$	14,122		$	9,817		Net of tax
	Actuarial (Gain) Loss on defined benefit pension plans
		Amortization of unrealized (gain) /loss			19,095			13,537		-1
					19,095			13,537		Total before tax
					-7,318			-5,308		Tax expense or benefit
				$	11,777		$	8,229		Net of tax
	Total reclassifications for the period			$	25,899		$	18,046		Net of tax
	(1) Included in the computation of net periodic pension cost (see Note 9 for additional details).

Business_Segment_Information_T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2013
Business Segment Information (Tables) [Abstract]	'
Schedule of segment reporting information by segment	'
					North America Segment		International Segment		Segment Total		Corporate		Total
	Three months ended September 30, 2013
		Net revenue external customers		$	2,436,141	$	1,222,026	$	3,658,167	$	7,965	$	3,666,132
		Inter - segment revenue			2,591		-		2,591		-2,591		-
		Revenue			2,438,732		1,222,026		3,660,758		5,374		3,666,132
		Depreciation and amortization			-83,251		-45,824		-129,075		-35,204		-164,279
		Operating income			415,533		204,458		619,991		-62,731		557,260
		Income (loss) from equity method investees			3,965		-102		3,863		1,431		5,294
		Capital expenditures, acquisitions and investments			284,453		53,260		337,713		36,768		374,481
	Three months ended September 30, 2012
		Net revenue external customers		$	2,248,724	$	1,163,362	$	3,412,086	$	5,852	$	3,417,938
		Inter - segment revenue			2,501		-		2,501		-2,501		-
		Revenue			2,251,225		1,163,362		3,414,587		3,351		3,417,938
		Depreciation and amortization			-79,446		-43,942		-123,388		-28,824		-152,212
		Operating income			420,316		195,264		615,580		-47,938		567,642
		Income (loss) from equity method investees			6,642		53		6,695		-1,378		5,317
		Capital expenditures, acquisitions and investments			108,286		55,255		163,541		49,650		213,191
	Nine months ended September 30, 2013
		Net revenue external customers		$	7,098,638	$	3,619,000	$	10,717,638	$	24,930	$	10,742,568
		Inter - segment revenue			5,437		-		5,437		-5,437		-
		Revenue			7,104,075		3,619,000		10,723,075		19,493		10,742,568
		Depreciation and amortization			-244,619		-136,779		-381,398		-98,035		-479,433
		Operating Income			1,178,192		597,229		1,775,421		-180,609		1,594,812
		Income (loss) from equity method investees			11,899		866		12,765		1,753		14,518
		Segment assets			14,238,874		6,034,705		20,273,579		2,260,941		22,534,520
			thereof investments in equity method investees		256,195		387,565		643,760		-3,857		639,903
		Capital expenditures, acquisitions and investments(1)			504,733		202,137		706,870		103,062		809,932
	Nine months ended September 30, 2012
		Net revenue external customers		$	6,602,000	$	3,470,353	$	10,072,353	$	22,313	$	10,094,666
		Inter - segment revenue			9,041		-		9,041		-9,041		-
		Revenue			6,611,041		3,470,353		10,081,394		13,272		10,094,666
		Depreciation and amortization			-230,575		-129,784		-360,359		-86,104		-446,463
		Operating Income			1,199,234		597,399		1,796,633		-137,200		1,659,433
		Income (loss) from equity method investees			17,962		182		18,144		-3,472		14,672
		Segment assets			13,806,253		5,835,643		19,641,896		2,218,437		21,860,333
			thereof investments in equity method investees		257,324		369,943		627,267		-4,189		623,078
		Capital expenditures, acquisitions and investments(2)			1,970,330		155,075		2,125,405		113,388		2,238,793
		(1) International acquisitions exclude $8,403 of non-cash acquisitions for 2013.
		(2) North America acquisitions exclude $484,699 of non-cash acquisitions and International acquisitions exclude $4,720 of non-cash acquisitions for 2012.

Supplementary_Cash_Flow_Inform1

Supplementary Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2013
Supplementary Cash Flow Information (Tables) [Abstract]	'
Schedule of supplemental Cash Flow information	'
			Nine months ended September 30,
			2013		2012
	Supplementary cash flow information:
		Cash paid for interest	$	337,143	$	316,734
		Cash paid for income taxes (1)	$	373,217	$	414,657
		Cash inflow for income taxes from stock option exercises	$	6,297	$	17,588
	Supplemental disclosures of cash flow information:
		Details for acquisitions:
		Assets acquired	$	-158,447	$	-2,434,645
		Liabilities assumed		19,923		282,789
		Noncontrolling interest subject to put provisions		16,317		86,729
		Noncontrolling interest		4,558		105,863
		Obligations assumed in connection with acquisition		8,403		4,720
		Cash paid		-109,246		-1,954,544
		Less cash acquired		5,471		171,795
		Net cash paid for acquisitions		-103,775		-1,782,749
		Cash paid for investments		-188,538		-386
		Cash paid for intangible assets		-5,143		-5,696
		Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets	$	-297,456	$	-1,788,831
		(1) Net of tax refund.

Supplemental_Condensed_Combini1

Supplemental Condensed Combining Information (Tables)	9 Months Ended
	Sep. 30, 2013
Supplemental Condensed Combining Information (Tables) [Abstract]	'
Income statement information segregated by issuers and guarantors	'
			For the nine months ended September 30, 2013
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	1,525,867		$	-		$	11,646,195		$	-2,429,494		$	10,742,568
	Cost of revenue			-			-			1,009,678			-			8,699,457			-2,403,587			7,305,548
		Gross profit		-			-			516,189			-			2,946,738			-25,907			3,437,020
	Operating expenses (income):
		Selling, general and administrative(1)		-			69,946			156,445			-91,072			1,590,946			21,439			1,747,704
		Research and development		-			-			54,985			-			39,687			-168			94,504
	Operating (loss) income			-			-69,946			304,759			91,072			1,316,105			-47,178			1,594,812
	Other (income) expense:
		Interest, net		-5,144			149,956			5,767			131,973			27,900			-			310,452
		Other, net		-			-1,001,160			238,088			-593,924			-			1,356,996			-
	Income (loss) before income taxes			5,144			781,258			60,904			553,023			1,288,205			-1,404,174			1,284,360
		Income tax expense (benefit)		1,867			20,261			67,212			-16,135			464,200			-116,532			420,873
	Net Income (loss)			3,277			760,997			-6,308			569,158			824,005			-1,287,642			863,487
	Net Income attributable to noncontrolling interests			-			-			-			-			-			102,490			102,490
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	3,277		$	760,997		$	-6,308		$	569,158		$	824,005		$	-1,390,132		$	760,997
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
			For the nine months ended September 30, 2012
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	1,394,861		$	-		$	10,838,232		$	-2,138,427		$	10,094,666
	Cost of revenue			-			-			890,050			-			8,014,600			-2,118,678			6,785,972
		Gross profit		-			-			504,811			-			2,823,632			-19,749			3,308,694
	Operating expenses (income):
		Selling, general and administrative (1)		-			27,391			148,291			17,612			1,336,427			36,213			1,565,934
		Research and development		-			-			51,298			-			32,029			-			83,327
	Operating (loss) income			-			-27,391			305,222			-17,612			1,455,176			-55,962			1,659,433
	Other (income) expense:
		Investment gain		-			-			-			-			-139,600			-			-139,600
		Interest, net		-5,125			160,923			1,580			111,308			43,204			-850			311,040
		Other, net		-			-1,175,959			201,306			-723,885			-			1,698,538			-
	Income (loss) before income taxes			5,125			987,645			102,336			594,965			1,551,572			-1,753,650			1,487,993
		Income tax expense (benefit)		1,877			57,948			88,213			-50,859			555,710			-190,535			462,354
	Net Income (loss)			3,248			929,697			14,123			645,824			995,862			-1,563,115			1,025,639
	Net Income attributable to noncontrolling interests			-			-			-			-			-			95,942			95,942
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	3,248		$	929,697		$	14,123		$	645,824		$	995,862		$	-1,659,057		$	929,697
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
Balance sheet information segregated by issuers and guarantors	'
				At September 30, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Current assets:
		Cash and cash equivalents		$	36		$	65		$	3,939		$	-		$	598,115		$	-		$	602,155
		Trade accounts receivable, less allowance for doubtful accounts			-			-			148,801			-			2,852,896			203			3,001,900
		Accounts receivable from related parties			1,252,224			1,936,651			1,134,433			1,638,081			4,651,538			-10,471,655			141,272
		Inventories			-			-			280,719			-			913,073			-140,437			1,053,355
		Prepaid expenses and other current assets			-			71,670			49,271			17			825,766			820			947,544
		Deferred taxes			-			-			-			-			295,581			2,368			297,949
			Total current assets		1,252,260			2,008,386			1,617,163			1,638,098			10,136,969			-10,608,701			6,044,175
	Property, plant and equipment, net				-			692			228,568			-			2,902,301			-123,657			3,007,904
	Intangible assets				-			609			74,649			-			596,216			-72			671,402
	Goodwill				-			-			56,664			-			11,464,148			-			11,520,812
	Deferred taxes				-			74,649			7,522			-			124,386			-65,269			141,288
	Other assets and notes receivables(1)				-			13,084,810			28,184			12,194,966			5,348,178			-29,507,199			1,148,939
		Total assets		$	1,252,260		$	15,169,146		$	2,012,750		$	13,833,064		$	30,572,198		$	-40,304,898		$	22,534,520
	Current liabilities:
		Accounts payable		$	-		$	285		$	29,090		$	-		$	476,030		$	-		$	505,405
		Accounts payable to related parties			-			2,231,722			816,334			1,569,192			6,028,772			-10,535,768			110,252
		Accrued expenses and other current liabilities			11,833			29,192			140,393			9,688			1,688,889			8,534			1,888,529
		Short-term borrowings			-			27			-			-			112,462			-			112,489
		Short-term borrowings from related parties			-			-			-			-			73,048			-			73,048
		Current portion of long-term debt and capital lease obligations			-			239,766			-			200,000			31,795			-			471,561
		Income tax payable			-			127,094			-			-			59,869			8,176			195,139
		Deferred taxes			-			3,001			7,546			-			64,397			-41,330			33,614
			Total current liabilities		11,833			2,631,087			993,363			1,778,880			8,535,262			-10,560,388			3,390,037
	Long term debt and capital lease obligations, less current portion				1,168,699			349,929			-			2,399,094			6,933,357			-3,078,776			7,772,303
	Long term borrowings from related parties				-			3,289,494			-			2,057,898			7,236			-5,354,628			-
	Other liabilities				-			5,600			14,629			-			250,842			31,684			302,755
	Pension liabilities				-			10,661			219,439			-			244,756			-			474,856
	Income tax payable				3,260			27,850			-			-			41,332			120,990			193,432
	Deferred taxes				-			-			-			-			692,077			-29,450			662,627
			Total liabilities		1,183,792			6,314,621			1,227,431			6,235,872			16,704,862			-18,870,568			12,796,010
	Noncontrolling interests subject to put provisions				-			-			0			-			641,021			-			641,021
	Total FMC-AG & Co. KGaA shareholders' equity				68,468			8,854,525			785,319			7,597,192			12,983,351			-21,434,330			8,854,525
	Noncontrolling interests not subject to put provisions				-			-			-			-			242,964			-			242,964
	Total equity				68,468			8,854,525			785,319			7,597,192			13,226,315			-21,434,330			9,097,489
		Total liabilities and equity		$	1,252,260		$	15,169,146		$	2,012,750		$	13,833,064		$	30,572,198		$	-40,304,898		$	22,534,520
	(1) Other Assets and notes receivables are presented net of investment in equity method investees.
				At December 31, 2012
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Current assets:
		Cash and cash equivalents		$	1		$	78		$	501		$	-		$	686,457		$	1,003		$	688,040
		Trade accounts receivable, less allowance for doubtful accounts			-			-			170,627			-			2,848,797			-			3,019,424
		Accounts receivable from related parties			1,269,471			2,257,445			1,449,317			3,562,953			4,398,630			-12,800,007			137,809
		Inventories			-			-			271,039			-			885,613			-119,843			1,036,809
		Prepaid expenses and other current assets			-			72,022			27,693			167			837,152			727			937,761
		Deferred taxes			-			-			-			-			311,280			-3,667			307,613
			Total current assets		1,269,472			2,329,545			1,919,177			3,563,120			9,967,929			-12,921,787			6,127,456
	Property, plant and equipment, net				-			611			206,873			-			2,856,000			-122,881			2,940,603
	Intangible assets				-			584			67,874			-			641,714			-56			710,116
	Goodwill				-			-			54,848			-			11,367,041			-			11,421,889
	Deferred taxes				-			51,111			10,123			-			131,452			-58,933			133,753
	Other assets and notes receivables (1)				-			12,675,998			650,255			11,766,104			-4,751,531			-19,348,645			992,181
		Total assets		$	1,269,472		$	15,057,849		$	2,909,150		$	15,329,224		$	20,212,605		$	-32,452,302		$	22,325,998
	Current liabilities:
		Accounts payable		$	-		$	1,935		$	41,114		$	-		$	579,245		$	-		$	622,294
		Accounts payable to related parties			-			2,234,205			491,525			1,598,852			8,663,240			-12,864,472			123,350
		Accrued expenses and other current liabilities			29,771			27,530			102,728			3,157			1,611,997			12,288			1,787,471
		Short-term borrowings			-			38			-			-			117,812			-			117,850
		Short-term borrowings from related parties			-			-			-			-			3,973			-			3,973
	Current portion of long-term debt and capital lease obligations			-			207,160			-			100,000			27,587			-			334,747
	Income tax payable			-			130,636			-			-			19,367			-			150,003
	Deferred taxes			-			1,622			8,126			-			61,774			-41,219			30,303
		Total current liabilities		29,771			2,603,126			643,493			1,702,009			11,084,995			-12,893,403			3,169,991
Long term debt and capital lease obligations, less current portion				1,172,397			285,049			-			2,559,340			7,020,190			-3,251,236			7,785,740
Long term borrowings from related parties				-			3,212,455			657,284			2,019,925			64,530			-5,898,020			56,174
Other liabilities				-			6,696			12,679			110,637			96,322			33,923			260,257
Pension liabilities				-			7,753			202,219			-			247,701			-			457,673
Income tax payable				2,113			264			-			-			52,684			146,581			201,642
Deferred taxes				-			-			-			-			685,158			-21,157			664,001
		Total liabilities		1,204,281			6,115,343			1,515,675			6,391,911			19,251,580			-21,883,312			12,595,478
Noncontrolling interests subject to put provisions				-			-			-			-			523,260			-			523,260
Total FMC-AG & Co. KGaA shareholders' equity				65,191			8,942,506			1,393,475			8,937,313			173,011			-10,568,990			8,942,506
Noncontrolling interests not subject to put provisions				-			-			-			-			264,754			-			264,754
Total equity				65,191			8,942,506			1,393,475			8,937,313			437,765			-10,568,990			9,207,260
	Total liabilities and equity		$	1,269,472		$	15,057,849		$	2,909,150		$	15,329,224		$	20,212,605		$	-32,452,302		$	22,325,998
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
Statement of cash flows information segregated by issuers and guarantors	'
					For the nine months ended September 30, 2013
					Issuer			Guarantors
					FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH		Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Operating Activities:
		Net income (loss)			$	3,277		$	760,997		$	-6,308		$	569,158		$	824,005		$	-1,287,642		$	863,487
		Adjustments to reconcile net income to net cash provided by (used in) operating activities:
		Equity affiliate income				-			-547,834			-			-593,924			-			1,141,758			-
			Depreciation and amortization			-			512			38,203			-			465,002			-24,284			479,433
			Change in deferred taxes, net			-			-27,091			1,372			-			25,028			-13,513			-14,204
			(Gain) loss on sale of fixed assets and investments			-			-12			-304			-			-6,086			-			-6,402
			(Gain) loss on investments			-			-			-66			-			-			66			-
			Compensation expense related to stock options			-			18,484			-			-			-			-			18,484
			Cash inflow (outflow) from hedging			-			-4,040			-			-			-			-			-4,040
			Investments in equity method investees, net			-			22,755			-			-			-11,965			-			10,790
		Changes in assets and liabilities, net of amounts from businesses acquired:
			Trade accounts receivable, net			-			-			17,616			-			-32,888			-198			-15,470
			Inventories			-			-			-3,210			-			-41,613			24,714			-20,109
			Prepaid expenses and other current and non-current assets			-			17,451			-18,106			-87,639			144,519			-1,061			55,164
			Accounts receivable from / payable to related parties			19,612			-127,112			93,191			98,809			-202,653			101,988			-16,165
			Accounts payable, accrued expenses and other current and non-current liabilities			-17,939			14,143			37,724			6,531			41,288			-3,004			78,743
			Income tax payable			1,147			20,440			-			-16,135			3,837			7,020			16,309
				Net cash provided by (used in) operating activities		6,097			148,693			160,112			-23,200			1,208,474			-54,156			1,446,020
	Investing Activities:
		Purchases of property, plant and equipment				-			-235			-56,354			-			-483,424			27,537			-512,476
		Proceeds from sale of property, plant and equipment				-			17			468			-			18,098			-			18,583
		Disbursement of loans to related parties				-			487,243			-			165,814			-			-653,057			-
		Acquisitions and investments, net of cash acquired, and purchases of intangible assets				-			-32,060			-4,670			-1,000			-292,784			33,058			-297,456
		Proceeds from divestitures				-			-			-			-			17,984			-			17,984
				Net cash provided by (used in) investing activities		-			454,965			-60,556			164,814			-740,126			-592,462			-773,365
	Financing Activities:
		Short-term borrowings, net				-			12,237			-96,214			-			94,366			-			10,389
		Long-term debt and capital lease obligations, net				-6,062			83,515			-			1,590,348			-2,309,633			653,057			11,225
		Increase (decrease) of accounts receivable securitization program				-			-			-			-			37,000			-			37,000
		Proceeds from exercise of stock options				-			68,577			-			-			6,298			-			74,875
		Proceeds from conversion of preference shares into ordinary shares				-			34,784			-			-			-			-			34,784
		Purchase of treasury stock				-			-505,014			-			-			-			-			-505,014
		Dividends paid				-			-296,134			-			-			-2,861			2,861			-296,134
		Capital increase (decrease)				-			-			-			-1,731,962			1,742,265			-10,303			-
		Distributions to noncontrolling interest				-			-			-			-			-162,239			-			-162,239
		Contributions from noncontrolling interest				-			-			-			-			52,357			-			52,357
				Net cash provided by (used in) financing activities		-6,062			-602,035			-96,214			-141,614			-542,447			645,615			-742,757
	Effect of exchange rate changes on cash and cash equivalents					-			-1,636			96			-			-14,243			-			-15,783
	Cash and Cash Equivalents:
	Net increase (decrease) in cash and cash equivalents					35			-13			3,438			-			-88,342			-1,003			-85,885
	Cash and cash equivalents at beginning of period					1			78			501			-			686,457			1,003			688,040
	Cash and cash equivalents at end of period				$	36		$	65		$	3,939		$	-		$	598,115		$	-		$	602,155
					For the nine months ended September 30, 2012
					Issuer			Guarantors									Non-Guarantor Subsidiaries
					FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH						Combining Adjustment				Combined Total
	Operating Activities:
		Net income (loss)			$	3,248		$	929,697		$	14,123		$	645,824		$	995,862		$	-1,563,115		$	1,025,639
		Adjustments to reconcile net income to net cash provided by (used in) operating activities:
		Equity affiliate income				-			-751,747			-			-723,885			-			1,475,632			-
			Depreciation and amortization			-			356			34,877			-			432,726			-21,496			446,463
			Change in deferred taxes, net			-			9,518			5,757			-			61,782			-5,669			71,388
			(Gain) loss on sale of fixed assets and investments			-			-39			-109			-			-31,674			-			-31,822
			Investment (gain)			-			-			-			-			-139,600			-			-139,600
			Compensation expense related to stock options			-			19,685			-			-			-			-			19,685
			Cash inflow (outflow) from hedging			-			1,318			-			-			-15,221			-			-13,903
			Investments in equity method investees, net			-			36,339			-			-			-11,256			-			25,083
		Changes in assets and liabilities, net of amounts from businesses acquired:
			Trade accounts receivable, net			-			-			-22,199			-			19,309			-			-2,890
			Inventories			-			-			-36,526			-			-19,777			13,089			-43,214
		Prepaid expenses and other current and non-current assets			-			136,300			-20,822			25,710			3,468			68			144,724
		Accounts receivable from / payable to related parties			5,230			-325,366			60,662			84,245			104,633			60,572			-10,024
		Accounts payable, accrued expenses and other current and non-current liabilities			-7,273			9,271			45,374			894			12,220			-1,466			59,020
		Income tax payable			106			-9,813			-			-50,859			1,257			-23,866			-83,175
			Net cash provided by (used in) operating activities		1,311			55,519			81,137			-18,071			1,413,729			-66,251			1,467,374
Investing Activities:
	Purchases of property, plant and equipment				-			-399			-58,818			-			-420,367			29,622			-449,962
	Proceeds from sale of property, plant and equipment				-			39			288			-			10,965			-			11,292
	Disbursement of loans to related parties				-			-28,315			90			960,074			-			-931,849			-
	Acquisitions and investments, net of cash acquired, and net purchases of intangible assets				-			-1,613,292			-1,138			-			-1,787,208			1,612,807			-1,788,831
	Proceeds from divestitures				-			44			-			-			231,747			-44			231,747
			Net cash provided by (used in) investing activities		-			-1,641,923			-59,578			960,074			-1,964,863			710,536			-1,995,754
Financing Activities:
	Short-term borrowings, net				-			26,118			-21,516			-			67,723			-			72,325
	Long-term debt and capital lease obligations, net				-1,312			1,751,969			-			-942,003			-844,418			931,849			896,085
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			12,500			-			12,500
	Proceeds from exercise of stock options				-			76,950			-			-			17,589			-			94,539
	Dividends paid				-			-271,733			-			-			-240			240			-271,733
	Capital increase (decrease)				-			-			-			-			1,576,424			-1,576,424			-
	Distributions to noncontrolling interest				-			-			-			-			-131,783			-			-131,783
	Contributions from noncontrolling interest				-			-			-			-			15,167			-			15,167
			Net cash provided by (used in) financing activities		-1,312			1,583,304			-21,516			-942,003			712,962			-644,335			687,100
Effect of exchange rate changes on cash and cash equivalents					-			5,853			-			-			-2,814			-			3,039
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					-1			2,753			43			-			159,014			-50			161,759
Cash and cash equivalents at beginning of period					1			2			144			-			457,145			-			457,292
Cash and cash equivalents at end of period				$	0		$	2,755		$	187		$	-		$	616,159		$	-50		$	619,051
Other comprehensive income statement segregated by issuers and guarantors	'
				For the nine months ended September 30, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	3,277		$	760,997		$	-6,308		$	569,158		$	824,005		$	-1,287,642		$	863,487
		Gain (loss) related to cash flow hedges			-			17,880			-			-			1,479			-			19,359
		Actuarial gain (loss) on defined benefit pension plans			-			97			1,906			16,926			166			-			19,095
		Gain (loss) related to foreign currency translation			-			-83,209			17,734			-			-37,229			5,802			-96,902
		Income tax (expense) benefit related to components of other comprehensive income			-			-5,172			-556			-6,677			-26			-			-12,431
	Other comprehensive income (loss), net of tax				-			-70,404			19,084			10,249			-35,610			5,802			-70,879
	Total comprehensive income			$	3,277		$	690,593		$	12,776		$	579,407		$	788,395		$	-1,281,840		$	792,608
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			100,936			100,936
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	3,277		$	690,593		$	12,776		$	579,407		$	788,395		$	-1,382,776		$	691,672
				For the nine months ended September 30, 2012
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	3,248		$	929,697		$	14,123		$	645,824		$	995,862		$	-1,563,115		$	1,025,639
		Gain (loss) related to cash flow hedges			-			-6,629			-9			11,725			9,806			-			14,893
		Actuarial gain (loss) on defined benefit pension plans			-			22			276			13,229			10			-			13,537
		Gain (loss) related to foreign currency translation			-			-14,402			2			-			49,371			-2,180			32,791
		Income tax (expense) benefit related to components of other comprehensive income			-			3,629			-76			-9,845			-22,242			-			-28,534
	Other comprehensive income (loss), net of tax				-			-17,380			193			15,109			36,945			-2,180			32,687
	Total comprehensive income			$	3,248		$	912,317		$	14,316		$	660,933		$	1,032,807		$	-1,565,295		$	1,058,326
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			97,183			97,183
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	3,248		$	912,317		$	14,316		$	660,933		$	1,032,807		$	-1,662,478		$	961,143

Acquisition_of_Liberty_Dialysi4

Acquisition of Liberty Dialysis Holdings (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Business Acquisition [Line Items]	'	'	'	'	'
Trade accounts receivable	$3,001,900	'	$3,001,900	'	$3,019,424
Other current assets	947,544	'	947,544	'	937,761
Goodwill	11,520,812	'	11,520,812	'	11,421,889
Income tax payable, current	-195,139	'	-195,139	'	-150,003
Short-term borrowings from related parties	-73,048	'	-73,048	'	-3,973
Cash Paid	-109,246	-1,954,544	-109,246	-1,954,544	'
Revenue	3,666,132	3,417,938	10,742,568	10,094,666	'
Operating income	557,260	567,642	1,594,812	1,659,433	'
Liberty Dialysis Holdings [Member]	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Other current assets	164,068	'	164,068	'	'
Trade accounts receivable	149,219	'	149,219	'	'
Other current assets	17,458	'	17,458	'	'
Deferred Tax Asset	14,932	'	14,932	'	'
Property, plant and equipment	168,335	'	168,335	'	'
Intangible assets and other assets	84,556	'	84,556	'	'
Goodwill	2,003,465	'	2,003,465	'	'
Acquisition Accounts Payable	105,403	'	105,403	'	'
Income tax payable, current	33,597	'	33,597	'	'
Short-term borrowings from related parties	72,101	'	72,101	'	'
Other Liabilities	39,923	'	39,923	'	'
Noncontrolling interests (subject and not subject to put provisions)	169,651	'	169,651	'	'
Total acquisition cost	2,181,358	'	2,181,358	'	'
Investment at acquisition date	-201,915	'	-201,915	'	'
Long Term Note Receivable Acquisitions	-282,784	'	-282,784	'	'
Total non-cash items	-484,699	'	-484,699	'	'
Cash Paid	$1,696,659	'	$1,696,659	'	'

Acquisition_of_Liberty_Dialysi5

Acquisition of Liberty Dialysis Holdings - Pro Forma (Details) (USD $)	9 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2012	Sep. 30, 2012
		LibertyAcquisitionProForma [Member]
Pro Forma [Line Items]	'	'
Pro forma net revenue	$10,197,670	$3,415,472
Pro forma net income attributable to the shareholders of FMC-AG & co. KGaA	$797,867	$268,467
Basic	2.62	0.88
Fully diluted	2.6	0.87

Related_Party_Transactions_Det

Related Party Transactions (Details)

9 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

USD ($)

USD ($)

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

General Partner [Member]

General Partner [Member]

General Partner [Member]

General Partner [Member]

APP Inc [Member]

APP Inc [Member]

Equity Method Investees [Member]

Fresenius SE Subsidiary [Member]

USD ($)

EUR (€)

Services Provided By Related Party [Member]

Services Provided By Related Party [Member]

Services Provided To Related Party [Member]

Services Provided To Related Party [Member]

Operating Lease Agreements [Member]

Operating Lease Agreements [Member]

Sales To Related Party [Member]

Sales To Related Party [Member]

Purchases From Related Party [Member]

Purchases From Related Party [Member]

Taxes Receivable [Member]

Taxes Receivable [Member]

USD ($)

EUR (€)

Services Provided By Related Party [Member]

Services Provided By Related Party [Member]

Purchases From Related Party [Member]

Purchases From Related Party [Member]

Sales To Related Party [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Related Party Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

FSE ownership percentage

31.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of transaction

'

'

'

'

$78,215

$60,634

$4,925

$4,396

$20,037

$18,779

$22,651

$16,802

$27,854

$35,572

$6,518

€ 4,827

'

'

$12,219

$12,243

$14,420

$12,820

$655

'

Due to related parties

$110,252

$123,350

$12,560

€ 9,300

'

'

'

'

'

'

'

'

'

'

'

'

$2,026

€ 1,500

'

'

'

'

'

$58,462

Interest rate

'

'

1.50%

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

1.80%

1.80%

'

'

'

'

'

6.10%

Date of repayment

23-May-14

'

31-Oct-12

31-Oct-12

'

'

'

'

'

'

'

'

'

'

'

'

20-Aug-14

20-Aug-14

'

'

'

'

'

14-Apr-13

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventories (Details) [Abstract]	'	'
Raw materials and purchased components	$192,352	$171,373
Work in process	86,629	83,258
Finished goods	646,659	627,338
Health care supplies	127,715	154,840
Inventories	$1,053,355	$1,036,809

Other_Assets_and_Notes_Receiva

Other Assets and Notes Receivable (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Accounts notes and loans receivable [LineItems]	'
Borrowings Available Under Notes Receivable	200,000
Notes Receivable Maturity Date	'date of July 4, 2020 (unless prepaid)
Notes Receivable Cash Interest Rate	10.75%
Notes Receivable PIK Interest Rate	11.75%
Availability Period End Date	'February 12, 2015
Notes Receivable Balance	$170,000
Notes Receivable Net Payment	165,542
Notes Receivable Interest Income	$2,538

Longterm_Debt_and_Capital_Leas2

Long-term Debt and Capital Lease Obligations (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Mar. 31, 2013

In Thousands, unless otherwise specified

Amended 2006 Senior Credit Agreement [Member]

Senior Credit Agreement 2012 Member [Member]

Senior Credit Agreement 2012 Member [Member]

RevolvingCreditEUR [Member]

RevolvingCreditEUR [Member]

Long Term Debt [Member]

Long Term Debt [Member]

Amended 2006 Senior Credit Agreement [Member]

Term Loan [Member]

Term Loan [Member]

Revolving Credit Facility [Member]

Senior Notes [Member]

Senior Notes [Member]

Euro Notes [Member]

Euro Notes [Member]

EIB Agreements [Member]

EIB Agreements [Member]

Accounts Receivable Facility [Member]

TermLoanA2012 [Member]

TermLoanA2012 [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior Credit Agreement

'

'

$2,869,194

'

'

'

'

'

'

'

$2,659,340

'

'

'

'

'

'

'

'

'

'

Senior Long Term Notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,786,706

4,743,442

45,579

51,951

189,070

324,334

'

Capital lease obligations

23,171

15,618

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other

131,144

163,802

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt and capital lease obligations

8,243,864

8,120,487

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less current maturities

471,561

334,747

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total long-term debt less current maturities

7,772,303

7,785,740

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revolving credit maximum amount available

3,825,250

3,859,700

'

'

'

600,000

'

659,700

'

'

'

2,550,000

2,600,000

600,000

'

'

'

'

'

'

'

Revolving credit balance outstanding

2,869,194

2,659,340

'

'

'

59,340

'

'

'

'

'

2,550,000

2,600,000

49,094

'

'

'

'

'

'

'

Maximum amount available

'

'

'

'

'

'

675,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance outstanding

'

'

'

'

'

'

270,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit outstanding which reduces available borrowings under the revolving credit facility

'

'

'

10,615

77,188

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65,622

Accounts receivable facility

'

'

'

'

'

'

'

'

$199,000

$162,000

'

'

'

'

'

'

'

'

'

'

'

Shortterm_Borrowings_and_Other

Short-term Borrowings and Other Financial Liabilities and Short-term Borrowings from Related Parties (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013
In Thousands, unless otherwise specified			Fresenius SE [Member]	General Partner [Member]
Related Party Transaction [Line Items]	'	'	'	'
Related Party Transaction Rate	'	'	1.50%	1.80%
Short-term borrowings and other financial liabilities	$112,489	$117,850	'	'
Short Term Borrowings Due To Related Parties Current Acquisitions	$73,048	$3,973	'	'

Stock_Options_Details

Stock Options (Details) (EUR €)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013
Stock Option 2011 Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Conditional capital increase	€ 12,000
Common stock no par values (in Euros)	1
Stock option expiration period	'8
Stock option vesting period	'4
Awards granted	2,110,388
Stock Option 2011 Plan [Member] | Euros [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted average exercise price	49.76
Stock Option 2011 Plan [Member] | USD [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted average exercise price	66.03
Weighted average fair value per share granted	11.84
Total fair value of granted shares	24,980
Stock Option 2011 Plan [Member] | Management Board General Partner [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Awards granted	328,680
Phantom Stock 2011 Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock option expiration period	'5
Stock option vesting period	'4
Awards granted	183,661
Phantom Stock 2011 Plan [Member] | Euros [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted average fair value per share granted	53.68
Phantom Stock 2011 Plan [Member] | USD [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted average fair value per share granted	69.41
Total fair value of granted shares	12,065
Phantom Stock 2011 Plan [Member] | Management Board General Partner [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Awards granted	25,006

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerators:	'	'	'	'
Income attributable to the Company	$272,974,000	$269,862,000	$760,997,000	$929,697,000
Less: Dividend preference on Preference shares	'	25,000	'	76,000
Income available to all classes of shares	272,974,000	269,837,000	760,997,000	929,621,000
Denominators:	'	'	'	'
Weighted average number of ordinary shares outstanding	301,310,149	301,531,173	302,158,886	300,720,312
Weighted average number of preference shares outstanding	0	3,971,607	2,590,857	3,968,082
Total weighted average shares outstanding	301,310,149	305,502,780	304,749,743	304,688,394
Potentially dilutive Ordinary shares	445,648	2,008,318	637,188	1,740,599
Potentially dilutive Preference shares	0	17,392	0	17,209
Total weighted average Ordinary shares outstanding assuming dilution	301,755,797	303,539,491	302,796,074	302,460,911
Total weighted average Preference shares outstanding assuming dilution	0	3,988,999	2,590,857	3,985,291
Basic income per Ordinary share	0.91	0.88	2.5	3.05
Fully diluted income per Ordinary share	$0.90	$0.88	$2.49	$3.03

Earnings_per_Share_Details_1

Earnings per Share (Details 1)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
	May 2013 [Member]	May 2013 [Member]	June 2013 [Member]	June 2013 [Member]	July 2013 [Member]	July 2013 [Member]	August 2013 [Member]	August 2013 [Member]	Total [Member]	Total [Member]
	USD ($)	EUR (€)	USD ($)	EUR (€)	USD ($)	EUR (€)	USD ($)	EUR (€)	USD ($)	EUR (€)
shares repurchased (line items)	'	'	'	'	'	'	'	'	'	'
average price paid per share	68.48	68.48	69.95	69.95	64.63	64.63	64.3	64.3	66.9	66.9
total number of shares purchased as part of publicly announced plans or programs	1,078,255	1,078,255	2,502,552	2,502,552	2,972,770	2,972,770	995,374	995,374	7,548,951	7,548,951
total value of shares repurchased	$73,842	€ 57,107	$175,047	€ 132,769	$192,124	€ 146,916	$64,001	€ 48,174	$505,014	€ 384,966
maximum value of shares that may yet be purchased under plans or programs as of the end of the period	$426,458	€ 327,893	$255,222	€ 195,124	$63,996	€ 48,208	'	'	'	'

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Components Of Net Periodic Benefit Cost [Abstract]	'	'	'	'
Service cost	$3,932	$2,645	$11,601	$7,982
Interest cost	6,635	6,590	20,130	19,528
Expected return on plan assets	-3,415	-3,796	-10,215	-11,446
Amortization of unrealized losses	6,318	4,794	19,095	13,537
Net periodic benefit costs	$13,470	$10,233	$40,611	$29,601

Noncontrolling_Interests_Subje2

Noncontrolling Interests Subject to Put Provisions (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Noncontrolling Interests Subject To Put Provisions (Details) [Abstract]	'	'	'	'	'
Potential obligations under the put provisions	$641,021	'	$641,021	'	$523,260
Temporary Equity [Line Items]	'	'	'	'	'
Noncontrolling interests subject to put provisions beginning balance	'	'	523,260	'	'
Dividends paid	'	'	296,134	'	271,733
Minority interest increase from stock issuance	'	'	-16,916	'	59,787
Minority interest decrease from distributions to noncontrolling interest holders	'	'	-26,262	'	26,428
Changes in fair value of noncontrolling interests	'	'	-105,389	'	18,880
Net Income	305,829	306,641	863,487	1,025,639	'
Other comprehensive income loss net of tax	33,730	87,276	-70,879	32,687	'
Noncontrolling interests subject to put provisions ending balance	641,021	'	641,021	'	523,260
Put provisions exercisable	252,319	'	252,319	'	'
Noncontrolling interests subject to put provisions [Member]	'	'	'	'	'
Temporary Equity [Line Items]	'	'	'	'	'
Noncontrolling interests subject to put provisions beginning balance	'	'	410,491	'	'
Dividends paid	'	'	-88,847	'	-114,536
Minority interest increase from stock issuance	'	'	8,556	'	134,643
Minority interest decrease from distributions to noncontrolling interest holders	'	'	14,626	'	16,565
Changes in fair value of noncontrolling interests	'	'	105,389	'	-18,880
Net Income	'	'	77,467	'	94,718
Other comprehensive income loss net of tax	'	'	570	'	259
Noncontrolling interests subject to put provisions ending balance	'	'	'	'	$410,491

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (Insurance Claims [Member], USD $)	Mar. 31, 2013
In Thousands, unless otherwise specified
Insurance Claims [Member]	'
Loss Contingencies [Line Items]	'
Loss Contingency Accrual Carrying Value Current	$115,000

Patient_Service_Revenue_Detail

Patient Service Revenue (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
In Thousands, unless otherwise specified
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	$6,689,847	$6,214,099
Medicare ESRD program	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	3,258,043	2,955,411
Hospitals	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	309,164	299,067
Private	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	2,833,762	2,671,895
Medicaid and other government sources	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	$288,878	$287,726

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	6 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Assets:	'	'	'	'	'
Cash and cash equivalents	'	$602,155	$688,040	$619,051	$457,292
Liabilities:	'	'	'	'	'
Short-term borrowings	'	112,489	117,850	'	'
Short-term borrowings from related parties	'	73,048	3,973	'	'
Noncontrolling interests subject to put provisions	'	641,021	523,260	'	'
Notional amount of foreign currency cash flow hedge derivatives	'	265,640	611,488	'	'
Notional amount of interest rate derivatives	'	1,380,878	1,574,667	'	'
Amount estimated to be transferred in the future from accumulated OCI into earnings	1,680	'	'	'	'
The time period estimated for the anticipated transfer of interest expense into earnings	'	'12 months	'	'	'
Derivative assets subject to master netting agreements	'	16,181	32,044	'	'
Derivative liabilities subject to master netting agreements	'	9,928	19,193	'	'
Derivative net assets subject to master netting agreements	'	11,242	20,773	'	'
Derivative net liabiltiies subject to master netting agreements	'	4,989	7,922	'	'
Euro Notes [Member]	'	'	'	'	'
Liabilities:	'	'	'	'	'
Senior Long Term Notes	'	45,579	51,951	'	'
Senior Notes [Member]	'	'	'	'	'
Liabilities:	'	'	'	'	'
Senior Long Term Notes	'	4,786,706	4,743,442	'	'
Carrying Reported Amount Fair Value Disclosure [Member]	'	'	'	'	'
Assets:	'	'	'	'	'
Cash and cash equivalents	'	602,155	688,040	'	'
Accounts receivable	'	3,143,172	3,157,233	'	'
Long-term notes receivable	'	165,648	0	'	'
Liabilities:	'	'	'	'	'
Accounts Payable	'	615,657	745,644	'	'
Short-term borrowings	'	185,537	121,823	'	'
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes	'	542,385	721,928	'	'
Senior Credit Agreement	'	2,869,194	2,659,340	'	'
Noncontrolling interests subject to put provisions	'	641,021	523,260	'	'
Carrying Reported Amount Fair Value Disclosure [Member] | Euro Notes [Member]	'	'	'	'	'
Liabilities:	'	'	'	'	'
Senior Long Term Notes	'	45,579	51,951	'	'
Carrying Reported Amount Fair Value Disclosure [Member] | Senior Notes [Member]	'	'	'	'	'
Liabilities:	'	'	'	'	'
Senior Long Term Notes	'	4,786,706	4,743,442	'	'
Portion At Fair Value Fair Value Disclosure [Member]	'	'	'	'	'
Assets:	'	'	'	'	'
Cash and cash equivalents	'	602,155	688,040	'	'
Accounts receivable	'	3,143,172	3,157,233	'	'
Long-term notes receivable	'	172,244	0	'	'
Liabilities:	'	'	'	'	'
Accounts Payable	'	615,657	745,644	'	'
Short-term borrowings	'	185,537	121,823	'	'
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes	'	542,385	721,928	'	'
Senior Credit Agreement	'	2,859,632	2,652,840	'	'
Noncontrolling interests subject to put provisions	'	641,021	523,260	'	'
Portion At Fair Value Fair Value Disclosure [Member] | Euro Notes [Member]	'	'	'	'	'
Liabilities:	'	'	'	'	'
Senior Long Term Notes	'	46,236	54,574	'	'
Portion At Fair Value Fair Value Disclosure [Member] | Senior Notes [Member]	'	'	'	'	'
Liabilities:	'	'	'	'	'
Senior Long Term Notes	'	$5,160,957	$5,296,325	'	'

Financial_Instruments_Details_

Financial Instruments (Details 1) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	$4,887	$8,781
Liabilities	-7,276	-13,918
Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	11,740	23,528
Liabilities	-4,949	-19,360
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member]	'	'
Derivatives Fair Value [Line Items]	'	'
Liabilities	-785	'
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	4,651	7,839
Liabilities	-2,117	-7,510
Foreign Exchange Contract Current [Member] | Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	10,853	23,396
Liabilities	-4,048	-19,068
Foreign Exchange Contract Non Current [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	236	942
Liabilities	'	-187
Foreign Exchange Contract Non Current [Member] | Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	887	132
Liabilities	-901	-292
Interest Rate Contract Non Current Dollar [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Liabilities	($4,374)	($6,221)

Financial_Instruments_Details_1

Financial Instruments (Details 2) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Designated As Hedging Instrument [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	($387)	$2,651
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	19,746	12,242
Designated As Hedging Instrument [Member] | Interest Rate Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	-2,544	-12,040
Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	2,157	14,691
Nondesignated as Hedging Instrument [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	-21,302	8,088
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Interest Rate Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	20,476	17,014
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	577	228
Interest Income Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	5,690	4,940
Cost Of Sale [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	-1,307	-5,000
Selling, General and Administrative Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	($26,992)	$3,148

Other_Comprehensive_Income_Rol

Other Comprehensive Income - Rollforward (Details) (USD $)	9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Balance	'	'	($489,244)	($482,719)
Other comprehensive income (loss) before reclassifications	'	'	-96,778	14,641
AOCI reclassifications	'	'	25,899	18,046
Other comprehensive income loss net of taxes	'	'	-70,879	32,687
Ending Balance OCI	-560,123	-450,032	'	'
Accumulated Net Gain Loss From Designated Or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Balance	'	'	-138,341	-136,221
Other comprehensive income (loss) before reclassifications	'	'	124	-18,150
AOCI reclassifications	'	'	14,122	9,817
Other comprehensive income loss net of taxes	'	'	14,246	-8,333
Ending Balance OCI	-124,095	-144,554	'	'
Accumulate benefit plans adjustment [Member]	'	'	'	'
Balance	'	'	-179,423	-111,215
AOCI reclassifications	'	'	11,777	8,229
Other comprehensive income loss net of taxes	'	'	11,777	8,229
Ending Balance OCI	-167,646	-102,986	'	'
Accumulated translation adjustments (Domain) [Member]	'	'	'	'
Balance	'	'	-174,349	-238,331
Other comprehensive income (loss) before reclassifications	'	'	-95,348	31,550
Other comprehensive income loss net of taxes	'	'	-95,348	31,550
Ending Balance OCI	-269,697	-206,781	'	'
Total, before non-controlling interests	'	'	'	'
Balance	'	'	-492,113	-485,767
Other comprehensive income (loss) before reclassifications	'	'	-95,224	13,400
AOCI reclassifications	'	'	25,899	18,046
Other comprehensive income loss net of taxes	'	'	-69,325	31,446
Ending Balance OCI	-561,438	-454,321	'	'
Noncontrolling interests not subject to put provisions [Member]	'	'	'	'
Balance	'	'	2,869	3,048
Other comprehensive income (loss) before reclassifications	'	'	-1,554	1,241
Other comprehensive income loss net of taxes	'	'	-1,554	1,241
Ending Balance OCI	$1,315	$4,289	'	'

Other_Comprehensive_Income_Rec

Other Comprehensive Income - Reclassifications (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Other comprehensive income derivatives qualifying as hedges net of tax period increase decrease abstract	'	'	'	'
Interest rate contracts	'	'	$20,476	$17,014
Foreign exchange contracts cost of revenue	'	'	-1,307	-5,000
Foreign exchange contracts interest	'	'	577	228
Total before tax	'	'	19,746	12,242
Tax expense or benefit	'	'	-5,624	-2,425
Net of tax	'	'	14,122	9,817
Other comprehensive income defined benefit plans adjustment net of tax period increase decrease abstract	'	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	6,318	4,794	19,095	13,537
Total before tax	'	'	19,095	13,537
Benefit plans tax expense	'	'	-7,318	-5,308
Benefit plans net of tax	'	'	11,777	8,229
Total reclassifications for the period	'	'	$25,899	$18,046

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'	'	'
Net revenue from external customers	$3,666,132	$3,417,938	$10,742,568	$10,094,666	'
Segment depreciation and amortization	-164,279	-152,212	-479,433	-446,463	'
Operating income	557,260	567,642	1,594,812	1,659,433	'
Income from equity method investees	5,294	5,317	14,518	14,672	'
Segment assets	22,534,520	'	22,534,520	'	22,325,998
thereof investment in equity method investees	639,903	'	639,903	'	637,373
Capital expenditures, acquisitions and investments	374,481	213,191	809,932	2,238,793	'
Segment Total [Member]	'	'	'	'	'
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'	'	'
Net revenue from external customers	3,658,167	3,412,086	10,717,638	10,072,353	'
Inter - segment revenue	2,591	2,501	'	9,041	'
Segment revenue	3,660,758	3,414,587	10,723,075	10,081,394	'
Segment depreciation and amortization	-129,075	-123,388	-381,398	-360,359	'
Operating income	619,991	615,580	1,775,421	1,796,633	'
Income from equity method investees	3,863	6,695	12,765	18,144	'
Segment assets	20,273,579	19,641,896	20,273,579	19,641,896	'
thereof investment in equity method investees	643,760	627,267	643,760	627,267	'
Capital expenditures, acquisitions and investments	337,713	163,541	706,870	2,125,405	'
North America [Member]	'	'	'	'	'
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'	'	'
Net revenue from external customers	2,436,141	2,248,724	7,098,638	6,602,000	'
Inter - segment revenue	2,591	2,501	5,437	9,041	'
Segment revenue	2,438,732	2,251,225	7,104,075	6,611,041	'
Segment depreciation and amortization	-83,251	-79,446	-244,619	-230,575	'
Operating income	415,533	420,316	1,178,192	1,199,234	'
Income from equity method investees	3,965	6,642	11,899	17,962	'
Segment assets	14,238,874	13,806,253	14,238,874	13,806,253	'
thereof investment in equity method investees	256,195	257,324	256,195	257,324	'
Capital expenditures, acquisitions and investments	284,453	108,286	504,733	1,970,330	'
Exclusion of non-cash acquisitions	'	'	6,000	'	'
International [Member]	'	'	'	'	'
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'	'	'
Net revenue from external customers	1,222,026	1,163,362	3,619,000	3,470,353	'
Inter - segment revenue	'	'	5,437	'	'
Segment revenue	1,222,026	1,163,362	3,619,000	3,470,353	'
Segment depreciation and amortization	-45,824	-43,942	-136,779	-129,784	'
Operating income	204,458	195,264	597,229	597,399	'
Income from equity method investees	-102	53	866	182	'
Segment assets	6,034,705	5,835,643	6,034,705	5,835,643	'
thereof investment in equity method investees	387,565	369,943	387,565	369,943	'
Capital expenditures, acquisitions and investments	53,260	55,255	202,137	155,075	'
Exclusion of non-cash acquisitions	'	'	1,731	8,884	'
Corporate1 [Member]	'	'	'	'	'
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'	'	'
Net revenue from external customers	7,965	5,852	24,930	22,313	'
Inter - segment revenue	-2,591	-2,501	-5,437	-9,041	'
Segment revenue	5,374	3,351	19,493	13,272	'
Segment depreciation and amortization	-35,204	-28,824	-98,035	-86,104	'
Operating income	-62,731	-47,938	-180,609	-137,200	'
Income from equity method investees	1,431	-1,378	1,753	-3,472	'
Segment assets	2,260,941	2,218,437	2,260,941	2,218,437	'
thereof investment in equity method investees	-3,857	-4,189	-3,857	-4,189	'
Capital expenditures, acquisitions and investments	36,768	49,650	103,062	113,388	'
Exclusion of non-cash acquisitions	'	'	'	$2,125	'

Supplemental_Condensed_Combini2

Supplemental Condensed Combining Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements of Income	'	'	'	'	'	'
Net revenue	$3,666,132	$3,417,938	$10,742,568	$10,094,666	'	'
Cost of revenues	2,497,003	2,305,627	7,305,548	6,785,972	'	'
Gross profit	1,169,129	1,112,311	3,437,020	3,308,694	'	'
Selling, general and administrative	'	'	1,747,704	1,565,934	'	'
Research and development	33,211	27,867	94,504	83,327	'	'
Operating income	557,260	567,642	1,594,812	1,659,433	'	'
Other (income) expense:	'	'	'	'	'	'
Interest, net	'	'	310,452	311,040	'	'
Gain on the sale of dialysis clinics	-597	-58	-9,397	'	'	'
Income before income taxes	454,088	459,677	1,284,360	1,487,993	'	'
Income tax expense	148,259	153,036	420,873	462,354	'	'
Net Income	305,829	306,641	863,487	1,025,639	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	-531	6,651	19,359	14,893	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	6,318	4,794	19,095	13,537	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	30,460	80,407	-96,902	32,791	'	'
Other comprehensive income loss tax	-2,517	-4,576	-12,431	-28,534	'	'
Less: Net income attributable to noncontrolling interests	32,855	36,779	102,490	95,942	'	'
Income attributable to the Company	272,974	269,862	760,997	929,697	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	602,155	619,051	602,155	619,051	688,040	457,292
Trade accounts receivable less allowance for doubtful accounts of $353,082 in 2013 and $328,893 in 2012	3,001,900	'	3,001,900	'	3,019,424	'
Accounts receivable from related parties	141,272	'	141,272	'	137,809	'
Inventories	1,053,355	'	1,053,355	'	1,036,809	'
Prepaid expenses and other current assets	947,544	'	947,544	'	937,761	'
Deferred tax asset, current	297,949	'	297,949	'	307,613	'
Total current assets	6,044,175	'	6,044,175	'	6,127,456	'
Property, plant and equipment, net	3,007,904	'	3,007,904	'	2,940,603	'
Intangible assets	671,402	'	671,402	'	710,116	'
Goodwill	11,520,812	'	11,520,812	'	11,421,889	'
Deferred tax asset, non-current	141,288	'	141,288	'	133,753	'
Total assets	22,534,520	'	22,534,520	'	22,325,998	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	505,405	'	505,405	'	622,294	'
Accounts payable to related parties	110,252	'	110,252	'	123,350	'
Accrued expenses and other current liabilities	1,888,529	'	1,888,529	'	1,787,471	'
Short-term borrowings and other financial liabilities	112,489	'	112,489	'	117,850	'
Short Term Borrowings Due To Related Parties Current Acquisitions	73,048	'	73,048	'	3,973	'
Current portion of long-term debt and capital lease obligations	471,561	'	471,561	'	334,747	'
Income tax payable, current	195,139	'	195,139	'	150,003	'
Deferred tax liability, current	33,614	'	33,614	'	30,303	'
Total current liabilities	3,390,037	'	3,390,037	'	3,169,991	'
Total long-term debt less current maturities	7,772,303	'	7,772,303	'	7,785,740	'
Other liabilities	302,755	'	302,755	'	260,257	'
Pension liabilities	474,856	'	474,856	'	457,673	'
Income tax payable, non-current	193,432	'	193,432	'	201,642	'
Deferred tax liability, non-current	662,627	'	662,627	'	664,001	'
Total liabilities	12,796,010	'	12,796,010	'	12,595,478	'
Noncontrolling interests subject to put provisions	641,021	'	641,021	'	523,260	'
Company shareholders' equity	8,854,525	'	8,854,525	'	8,942,506	'
Minority interest	242,964	'	242,964	'	264,754	'
Total equity	9,097,489	'	9,097,489	'	9,207,260	8,061,017
Total liabilities and equity	22,534,520	'	22,534,520	'	22,325,998	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'
Net Income	305,829	306,641	863,487	1,025,639	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	-531	6,651	19,359	14,893	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	6,318	4,794	19,095	13,537	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	30,460	80,407	-96,902	32,791	'	'
Other comprehensive income loss tax	-2,517	-4,576	-12,431	-28,534	'	'
Other comprehensive income (loss), net of tax	33,730	87,276	-70,879	32,687	'	'
Total comprehensive income	339,559	393,917	792,608	1,058,326	'	'
Comprehensive income attributable to noncontrolling interests	-33,619	-37,934	-100,936	-97,183	'	'
Comprehensive income attributable to the Company	305,940	355,983	691,672	961,143	'	'
FMCH [Member]	'	'	'	'	'	'
Other (income) expense:	'	'	'	'	'	'
Income attributable to the Company	'	'	569,158	'	'	'
Issuers [Member] | FMCH [Member]	'	'	'	'	'	'
Other (income) expense:	'	'	'	'	'	'
Interest, net	'	'	'	111,308	'	'
Issuers [Member] | FMC US Finance [Member]	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'
Selling, general and administrative	'	'	'	0	'	'
Operating income	'	'	'	0	'	'
Other (income) expense:	'	'	'	'	'	'
Interest, net	'	'	-5,144	-5,125	'	'
Income before income taxes	'	'	5,144	5,125	'	'
Income tax expense	'	'	1,867	1,877	'	'
Net Income	'	'	3,277	3,248	'	'
Income attributable to the Company	'	'	3,277	3,248	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	36	0	36	0	1	'
Accounts receivable from related parties	1,252,224	'	1,252,224	'	1,269,471	'
Total current assets	1,252,260	'	1,252,260	'	1,269,472	'
Total assets	1,252,260	'	1,252,260	'	1,269,472	'
Current liabilities:	'	'	'	'	'	'
Accounts payable to related parties	'	'	'	'	0	'
Accrued expenses and other current liabilities	11,833	'	11,833	'	29,771	'
Income tax payable, current	'	'	'	'	0	'
Total current liabilities	11,833	'	11,833	'	29,771	'
Total long-term debt less current maturities	1,168,699	'	1,168,699	'	1,172,397	'
Income tax payable, non-current	3,260	'	3,260	'	'	'
Total liabilities	1,183,792	'	1,183,792	'	1,204,281	'
Company shareholders' equity	68,468	'	68,468	'	65,191	'
Total equity	68,468	'	68,468	'	65,191	'
Total liabilities and equity	1,252,260	'	1,252,260	'	1,269,472	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'
Net Income	'	'	3,277	3,248	'	'
Total comprehensive income	'	'	3,277	'	'	'
Comprehensive income attributable to the Company	'	'	3,277	'	'	'
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member]	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'
Selling, general and administrative	'	'	69,946	27,391	'	'
Operating income	'	'	-69,946	-27,391	'	'
Other (income) expense:	'	'	'	'	'	'
Interest, net	'	'	149,956	160,923	'	'
Other, net	'	'	-1,001,160	-1,175,959	'	'
Income before income taxes	'	'	781,258	987,645	'	'
Income tax expense	'	'	20,261	57,948	'	'
Net Income	'	'	760,997	929,697	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	17,880	-6,629	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	97	22	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-83,209	-14,402	'	'
Other comprehensive income loss tax	'	'	-5,172	3,629	'	'
Income attributable to the Company	'	'	760,997	929,697	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	65	2,755	65	2,755	78	2
Accounts receivable from related parties	1,936,651	'	1,936,651	'	2,257,445	'
Prepaid expenses and other current assets	71,670	'	71,670	'	72,022	'
Deferred tax asset, current	'	'	'	'	0	'
Total current assets	2,008,386	'	2,008,386	'	2,329,545	'
Property, plant and equipment, net	692	'	692	'	611	'
Intangible assets	609	'	609	'	584	'
Deferred tax asset, non-current	74,649	'	74,649	'	51,111	'
Other assets	13,084,810	'	13,084,810	'	12,675,998	'
Total assets	15,169,146	'	15,169,146	'	15,057,849	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	285	'	285	'	1,935	'
Accounts payable to related parties	2,231,722	'	2,231,722	'	2,234,205	'
Accrued expenses and other current liabilities	29,192	'	29,192	'	27,530	'
Short-term borrowings and other financial liabilities	27	'	27	'	38	'
Current portion of long-term debt and capital lease obligations	239,766	'	239,766	'	207,160	'
Income tax payable, current	127,094	'	127,094	'	130,636	'
Total current liabilities	2,631,087	'	2,631,087	'	2,603,126	'
Total long-term debt less current maturities	349,929	'	349,929	'	285,049	'
Long term borrowings from related parties	3,289,494	'	3,289,494	'	3,212,455	'
Other liabilities	5,600	'	5,600	'	6,696	'
Pension liabilities	10,661	'	10,661	'	7,753	'
Income tax payable, non-current	27,850	'	27,850	'	264	'
Total liabilities	6,314,621	'	6,314,621	'	6,115,343	'
Company shareholders' equity	8,854,525	'	8,854,525	'	8,942,506	'
Total equity	8,854,525	'	8,854,525	'	8,942,506	'
Total liabilities and equity	15,169,146	'	15,169,146	'	15,057,849	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'
Net Income	'	'	760,997	929,697	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	17,880	-6,629	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	97	22	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-83,209	-14,402	'	'
Other comprehensive income loss tax	'	'	-5,172	3,629	'	'
Other comprehensive income (loss), net of tax	'	'	-70,404	-17,380	'	'
Total comprehensive income	'	'	690,593	912,317	'	'
Comprehensive income attributable to the Company	'	'	690,593	912,317	'	'
Guarantors [Member] | D GmbH [Member]	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'
Net revenue	'	'	1,525,867	1,394,861	'	'
Cost of revenues	'	'	1,009,678	890,050	'	'
Gross profit	'	'	516,189	504,811	'	'
Selling, general and administrative	'	'	156,445	148,291	'	'
Research and development	'	'	54,985	51,298	'	'
Operating income	'	'	304,759	305,222	'	'
Other (income) expense:	'	'	'	'	'	'
Interest, net	'	'	5,767	1,580	'	'
Other, net	'	'	238,088	201,306	'	'
Income before income taxes	'	'	60,904	102,336	'	'
Income tax expense	'	'	67,212	88,213	'	'
Net Income	'	'	-6,308	14,123	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	'	-9	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	1,906	276	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	17,734	2	'	'
Other comprehensive income loss tax	'	'	-556	-76	'	'
Income attributable to the Company	'	'	-6,308	14,123	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	3,939	187	3,939	187	501	144
Trade accounts receivable less allowance for doubtful accounts of $353,082 in 2013 and $328,893 in 2012	148,801	'	148,801	'	170,627	'
Accounts receivable from related parties	1,134,433	'	1,134,433	'	1,449,317	'
Inventories	280,719	'	280,719	'	271,039	'
Prepaid expenses and other current assets	49,271	'	49,271	'	27,693	'
Total current assets	1,617,163	'	1,617,163	'	1,919,177	'
Property, plant and equipment, net	228,568	'	228,568	'	206,873	'
Intangible assets	74,649	'	74,649	'	67,874	'
Goodwill	56,664	'	56,664	'	54,848	'
Deferred tax asset, non-current	7,522	'	7,522	'	10,123	'
Other assets	28,184	'	28,184	'	650,255	'
Total assets	2,012,750	'	2,012,750	'	2,909,150	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	29,090	'	29,090	'	41,114	'
Accounts payable to related parties	816,334	'	816,334	'	491,525	'
Accrued expenses and other current liabilities	140,393	'	140,393	'	102,728	'
Deferred tax liability, current	7,546	'	7,546	'	8,126	'
Total current liabilities	993,363	'	993,363	'	643,493	'
Long term borrowings from related parties	0	'	0	'	657,284	'
Other liabilities	14,629	'	14,629	'	12,679	'
Pension liabilities	219,439	'	219,439	'	202,219	'
Total liabilities	1,227,431	'	1,227,431	'	1,515,675	'
Company shareholders' equity	785,319	'	785,319	'	1,393,475	'
Total equity	785,319	'	785,319	'	1,393,475	'
Total liabilities and equity	2,012,750	'	2,012,750	'	2,909,150	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'
Net Income	'	'	-6,308	14,123	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	'	-9	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	1,906	276	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	17,734	2	'	'
Other comprehensive income loss tax	'	'	-556	-76	'	'
Other comprehensive income (loss), net of tax	'	'	19,084	193	'	'
Total comprehensive income	'	'	12,776	14,316	'	'
Comprehensive income attributable to the Company	'	'	12,776	14,316	'	'
Guarantors [Member] | FMCH [Member]	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'
Selling, general and administrative	'	'	-91,072	17,612	'	'
Operating income	'	'	91,072	-17,612	'	'
Other (income) expense:	'	'	'	'	'	'
Interest, net	'	'	131,973	'	'	'
Other, net	'	'	-593,924	-723,885	'	'
Income before income taxes	'	'	553,023	594,965	'	'
Income tax expense	'	'	-16,135	-50,859	'	'
Net Income	'	'	569,158	645,824	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	'	11,725	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	16,926	13,229	'	'
Other comprehensive income loss tax	'	'	-6,677	-9,845	'	'
Income attributable to the Company	'	'	'	645,824	'	'
Current assets:	'	'	'	'	'	'
Accounts receivable from related parties	1,638,081	'	1,638,081	'	3,562,953	'
Prepaid expenses and other current assets	17	'	17	'	167	'
Total current assets	1,638,098	'	1,638,098	'	3,563,120	'
Other assets	12,194,966	'	12,194,966	'	11,766,104	'
Total assets	13,833,064	'	13,833,064	'	15,329,224	'
Current liabilities:	'	'	'	'	'	'
Accounts payable to related parties	1,569,192	'	1,569,192	'	1,598,852	'
Accrued expenses and other current liabilities	9,688	'	9,688	'	3,157	'
Current portion of long-term debt and capital lease obligations	200,000	'	200,000	'	100,000	'
Total current liabilities	1,778,880	'	1,778,880	'	1,702,009	'
Total long-term debt less current maturities	'	'	'	'	2,559,340	'
Long term borrowings from related parties	2,057,898	'	2,057,898	'	2,019,925	'
Other liabilities	'	'	'	'	110,637	'
Total liabilities	6,235,872	'	6,235,872	'	6,391,911	'
Company shareholders' equity	7,597,192	'	7,597,192	'	8,937,313	'
Total equity	7,597,192	'	7,597,192	'	8,937,313	'
Total liabilities and equity	13,833,064	'	13,833,064	'	15,329,224	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'
Net Income	'	'	569,158	645,824	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	'	11,725	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	16,926	13,229	'	'
Other comprehensive income loss tax	'	'	-6,677	-9,845	'	'
Other comprehensive income (loss), net of tax	'	'	10,249	15,109	'	'
Total comprehensive income	'	'	579,407	660,933	'	'
Comprehensive income attributable to the Company	'	'	579,407	660,933	'	'
Non Guarantor Subsidiaries [Member]	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'
Net revenue	'	'	11,646,195	10,838,232	'	'
Cost of revenues	'	'	8,699,457	8,014,600	'	'
Gross profit	'	'	2,946,738	2,823,632	'	'
Selling, general and administrative	'	'	1,590,946	1,336,427	'	'
Research and development	'	'	39,687	32,029	'	'
Operating income	'	'	1,316,105	1,455,176	'	'
Other (income) expense:	'	'	'	'	'	'
Interest, net	'	'	27,900	43,204	'	'
Gain on the sale of dialysis clinics	'	'	0	'	'	'
Income before income taxes	'	'	1,288,205	1,551,572	'	'
Income tax expense	'	'	464,200	555,710	'	'
Net Income	'	'	824,005	995,862	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	1,479	9,806	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	166	10	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-37,229	49,371	'	'
Other comprehensive income loss tax	'	'	-26	-22,242	'	'
Income attributable to the Company	'	'	824,005	995,862	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	598,115	616,159	598,115	616,159	686,457	457,145
Trade accounts receivable less allowance for doubtful accounts of $353,082 in 2013 and $328,893 in 2012	2,852,896	'	2,852,896	'	2,848,797	'
Accounts receivable from related parties	4,651,538	'	4,651,538	'	4,398,630	'
Inventories	913,073	'	913,073	'	885,613	'
Prepaid expenses and other current assets	825,766	'	825,766	'	837,152	'
Deferred tax asset, current	295,581	'	295,581	'	311,280	'
Total current assets	10,136,969	'	10,136,969	'	9,967,929	'
Property, plant and equipment, net	2,902,301	'	2,902,301	'	2,856,000	'
Intangible assets	596,216	'	596,216	'	641,714	'
Goodwill	11,464,148	'	11,464,148	'	11,367,041	'
Deferred tax asset, non-current	124,386	'	124,386	'	131,452	'
Other assets	5,348,178	'	5,348,178	'	-4,751,531	'
Total assets	30,572,198	'	30,572,198	'	20,212,605	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	476,030	'	476,030	'	579,245	'
Accounts payable to related parties	6,028,772	'	6,028,772	'	8,663,240	'
Accrued expenses and other current liabilities	1,688,889	'	1,688,889	'	1,611,997	'
Short-term borrowings and other financial liabilities	112,462	'	112,462	'	117,812	'
Short Term Borrowings Due To Related Parties Current Acquisitions	73,048	'	73,048	'	3,973	'
Current portion of long-term debt and capital lease obligations	31,795	'	31,795	'	27,587	'
Income tax payable, current	59,869	'	59,869	'	19,367	'
Deferred tax liability, current	64,397	'	64,397	'	61,774	'
Total current liabilities	8,535,262	'	8,535,262	'	11,084,995	'
Total long-term debt less current maturities	6,933,357	'	6,933,357	'	7,020,190	'
Long term borrowings from related parties	7,236	'	7,236	'	64,530	'
Other liabilities	250,842	'	250,842	'	96,322	'
Pension liabilities	244,756	'	244,756	'	247,701	'
Income tax payable, non-current	41,332	'	41,332	'	52,684	'
Deferred tax liability, non-current	692,077	'	692,077	'	685,158	'
Total liabilities	16,704,862	'	16,704,862	'	19,251,580	'
Noncontrolling interests subject to put provisions	641,021	'	641,021	'	523,260	'
Company shareholders' equity	12,983,351	'	12,983,351	'	173,011	'
Minority interest	242,964	'	242,964	'	264,754	'
Total equity	13,226,315	'	13,226,315	'	437,765	'
Total liabilities and equity	30,572,198	'	30,572,198	'	20,212,605	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'
Net Income	'	'	824,005	995,862	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	1,479	9,806	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	166	10	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-37,229	49,371	'	'
Other comprehensive income loss tax	'	'	-26	-22,242	'	'
Other comprehensive income (loss), net of tax	'	'	-35,610	36,945	'	'
Total comprehensive income	'	'	788,395	1,032,807	'	'
Comprehensive income attributable to the Company	'	'	788,395	1,032,807	'	'
Combining Adjustment [Member]	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'
Net revenue	'	'	-2,429,494	-2,138,427	'	'
Cost of revenues	'	'	-2,403,587	-2,118,678	'	'
Gross profit	'	'	-25,907	-19,749	'	'
Selling, general and administrative	'	'	21,439	36,213	'	'
Operating income	'	'	-47,178	-55,962	'	'
Other (income) expense:	'	'	'	'	'	'
Interest, net	'	'	0	-850	'	'
Other, net	'	'	1,356,996	1,698,538	'	'
Income before income taxes	'	'	-1,404,174	-1,753,650	'	'
Income tax expense	'	'	-116,532	-190,535	'	'
Net Income	'	'	-1,287,642	-1,563,115	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	5,802	-2,180	'	'
Less: Net income attributable to noncontrolling interests	'	'	102,490	95,942	'	'
Income attributable to the Company	'	'	-1,390,132	-1,659,057	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	0	'	0	'	'	0
Accounts receivable from related parties	-10,471,655	'	-10,471,655	'	-12,800,007	'
Inventories	-140,437	'	-140,437	'	-119,843	'
Prepaid expenses and other current assets	820	'	820	'	727	'
Deferred tax asset, current	2,368	'	2,368	'	-3,667	'
Total current assets	-10,608,701	'	-10,608,701	'	-12,921,787	'
Property, plant and equipment, net	-123,657	'	-123,657	'	-122,881	'
Deferred tax asset, non-current	-65,269	'	-65,269	'	-58,933	'
Other assets	-29,507,199	'	-29,507,199	'	-19,348,645	'
Total assets	-40,304,898	'	-40,304,898	'	-32,452,302	'
Current liabilities:	'	'	'	'	'	'
Accounts payable to related parties	-10,535,768	'	-10,535,768	'	-12,864,472	'
Accrued expenses and other current liabilities	8,534	'	8,534	'	12,288	'
Short Term Borrowings Due To Related Parties Current Acquisitions	0	'	0	'	0	'
Income tax payable, current	8,176	'	8,176	'	'	'
Deferred tax liability, current	-41,330	'	-41,330	'	-41,219	'
Total current liabilities	-10,560,388	'	-10,560,388	'	-12,893,403	'
Total long-term debt less current maturities	-3,078,776	'	-3,078,776	'	-3,251,236	'
Long term borrowings from related parties	-5,354,628	'	-5,354,628	'	-5,898,020	'
Other liabilities	31,684	'	31,684	'	33,923	'
Income tax payable, non-current	120,990	'	120,990	'	146,581	'
Deferred tax liability, non-current	-29,450	'	-29,450	'	-21,157	'
Total liabilities	-18,870,568	'	-18,870,568	'	-21,883,312	'
Company shareholders' equity	-21,434,330	'	-21,434,330	'	-10,568,990	'
Total equity	-21,434,330	'	-21,434,330	'	-10,568,990	'
Total liabilities and equity	-40,304,898	'	-40,304,898	'	-32,452,302	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'
Net Income	'	'	-1,287,642	-1,563,115	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	5,802	-2,180	'	'
Other comprehensive income (loss), net of tax	'	'	5,802	-2,180	'	'
Total comprehensive income	'	'	-1,281,840	-1,565,295	'	'
Comprehensive income attributable to noncontrolling interests	'	'	-100,936	-97,183	'	'
Comprehensive income attributable to the Company	'	'	($1,382,776)	($1,662,478)	'	'

Supplementary_Cash_Flow_Inform2

Supplementary Cash Flow Information (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Supplementary cash flow information:	'	'
Cash paid for interest	$337,143	$316,734
Cash paid for income taxes, net of tax refund	373,217	414,657
Cash inflow for income taxes from stock option exercises	6,297	17,588
Supplemental disclosures of cash flow information, details for acquisitions:	'	'
Assets acquired	-158,447	-2,434,645
Liabilities assumed	19,923	282,789
Noncontrolling interest	4,558	105,863
Notes assumed in connection with acquisition	8,403	4,720
Noncontrolling Interest Subject To Put Provisions	16,317	86,729
Cash Paid	-109,246	-1,954,544
Less cash acquired in acquisition	5,471	171,795
Net cash paid for acquisitions	-103,775	-1,782,749
CashPaidForInvestments	-188,538	-386
Cash Paid For Intangible Assets	-5,143	-5,696
Cash Paid For Acquisitions And Investments Net Of Cash Acquired And Purchases Of Intangible Assets	($297,456)	($1,788,831)

Supplemental_Condensed_Combini3

Supplemental Condensed Combining Information (Details 1) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Operating Activities:	'	'	'	'
Net Income	$305,829	$306,641	$863,487	$1,025,639
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	'	'	479,433	446,463
Change in deferred taxes, net	'	'	-14,204	71,388
(Gain) loss on sale of fixed assets and investments	'	'	-6,402	-31,822
Stock Option Compensation Expense	'	'	18,484	19,685
Cash outflow from hedging	'	'	-4,040	-13,903
Investment gain	0	0	0	139,600
Dividend income from equity method investees	'	'	10,790	25,083
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Trade accounts receivable, net	'	'	-15,470	-2,890
Inventories, net	'	'	-20,109	-43,214
Prepaid expenses, other current and non-current assets	'	'	55,164	144,724
Accounts receivable from/payable to related parties	'	'	-16,165	-10,024
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	78,743	59,020
Income tax payable	'	'	16,309	-83,175
Net cash provided by (used in) operating activities	'	'	1,446,020	1,467,374
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	-512,476	-449,962
Proceeds from sale of property, plant and equipment	'	'	18,583	11,292
Disbursements of loans to related parties	'	'	'	0
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	-297,456	-1,788,831
Proceeds from divestitures	'	'	17,984	231,747
Net cash (used in) provided by investing activities	'	'	-773,365	-1,995,754
Financing Activities:	'	'	'	'
Short-term borrowings, net	'	'	10,389	72,325
Long-term debt and capital lease obligations, net	'	'	11,225	896,085
Increase (decrease) of accounts receivable securitization program	'	'	37,000	12,500
Proceeds from exercise of stock options	'	'	74,875	94,539
Payment of dividends [N]	'	'	-296,134	-271,733
Capital (decrease) increase	'	'	'	0
Distributions to noncontrolling interests	'	'	162,239	131,783
Contributions from noncontrolling interests	'	'	52,357	15,167
Net cash (used in) provided by financing activities	'	'	-742,757	687,100
Effect of exchange rate changes on cash and cash equivalents	'	'	-15,783	3,039
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	-85,885	161,759
Cash and cash equivalents at beginning of period	'	'	688,040	457,292
Cash and cash equivalents at end of period	602,155	619,051	602,155	619,051
Issuers [Member]	'	'	'	'
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Net cash provided by (used in) operating activities	'	'	6,097	'
Issuers [Member] | Total FMC-AG and Co. KGaA [Member]	'	'	'	'
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	'	'	'	-751,747
Issuers [Member] | FMC US Finance [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	3,277	3,248
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Accounts receivable from/payable to related parties	'	'	19,612	5,230
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	'	-7,273
Income tax payable	'	'	1,147	106
Net cash provided by (used in) operating activities	'	'	'	1,311
Financing Activities:	'	'	'	'
Long-term debt and capital lease obligations, net	'	'	-6,062	-1,312
Capital (decrease) increase	'	'	'	0
Net cash (used in) provided by financing activities	'	'	-6,062	-1,312
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	'	-1
Cash and cash equivalents at beginning of period	'	'	1	'
Cash and cash equivalents at end of period	36	0	36	0
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	760,997	929,697
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	'	'	-547,834	'
Depreciation and amortization	'	'	512	356
Change in deferred taxes, net	'	'	-27,091	9,518
(Gain) loss on sale of fixed assets and investments	'	'	-12	-39
Loss (gain) on investments	'	'	'	0
Stock Option Compensation Expense	'	'	18,484	19,685
Cash outflow from hedging	'	'	-4,040	-1,318
Dividend income from equity method investees	'	'	-22,755	-36,339
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Prepaid expenses, other current and non-current assets	'	'	17,451	136,300
Accounts receivable from/payable to related parties	'	'	-127,112	-325,366
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	14,143	9,271
Income tax payable	'	'	20,440	-9,813
Net cash provided by (used in) operating activities	'	'	148,693	55,519
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	-235	-399
Proceeds from sale of property, plant and equipment	'	'	17	'
Disbursements of loans to related parties	'	'	487,243	-28,315
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	-32,060	-1,613,292
Proceeds from divestitures	'	'	0	'
Net cash (used in) provided by investing activities	'	'	454,965	-1,641,923
Financing Activities:	'	'	'	'
Short-term borrowings, net	'	'	12,237	26,118
Long-term debt and capital lease obligations, net	'	'	83,515	1,751,969
Proceeds from exercise of stock options	'	'	68,577	76,950
Payment of dividends [N]	'	'	-296,134	-271,733
Treasury Stock Purchased	'	'	-505,014	'
Net cash (used in) provided by financing activities	'	'	-602,035	1,583,304
Effect of exchange rate changes on cash and cash equivalents	'	'	-1,636	5,853
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	-13	2,753
Cash and cash equivalents at beginning of period	'	'	78	2
Cash and cash equivalents at end of period	65	2,755	65	2,755
Guarantors [Member] | D GmbH [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	-6,308	14,123
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	'	'	38,203	34,877
Change in deferred taxes, net	'	'	1,372	5,757
(Gain) loss on sale of fixed assets and investments	'	'	-304	-109
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Trade accounts receivable, net	'	'	17,616	-22,199
Inventories, net	'	'	-3,210	-36,526
Prepaid expenses, other current and non-current assets	'	'	-18,106	-20,822
Accounts receivable from/payable to related parties	'	'	93,191	60,662
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	37,724	45,374
Net cash provided by (used in) operating activities	'	'	160,112	81,137
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	-56,354	-58,818
Proceeds from sale of property, plant and equipment	'	'	468	288
Disbursements of loans to related parties	'	'	0	90
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	-4,670	-1,138
Net cash (used in) provided by investing activities	'	'	-60,556	-59,578
Financing Activities:	'	'	'	'
Short-term borrowings, net	'	'	-96,214	-21,516
Net cash (used in) provided by financing activities	'	'	-96,214	-21,516
Effect of exchange rate changes on cash and cash equivalents	'	'	96	0
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	3,438	43
Cash and cash equivalents at beginning of period	'	'	501	144
Cash and cash equivalents at end of period	3,939	187	3,939	187
Guarantors [Member] | FMCH [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	569,158	645,824
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	'	'	-593,924	-723,885
Depreciation and amortization	'	'	'	0
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Prepaid expenses, other current and non-current assets	'	'	-87,639	25,710
Accounts receivable from/payable to related parties	'	'	98,809	84,245
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	6,531	894
Income tax payable	'	'	-16,135	-50,859
Net cash provided by (used in) operating activities	'	'	-23,200	-18,071
Investing Activities:	'	'	'	'
Disbursements of loans to related parties	'	'	165,814	960,074
Net cash (used in) provided by investing activities	'	'	164,814	960,074
Financing Activities:	'	'	'	'
Short-term borrowings, net	'	'	'	0
Long-term debt and capital lease obligations, net	'	'	1,590,348	-942,003
Capital (decrease) increase	'	'	-1,731,962	0
Net cash (used in) provided by financing activities	'	'	-141,614	-942,003
Non Guarantor Subsidiaries [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	824,005	995,862
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	'	'	465,002	432,726
Change in deferred taxes, net	'	'	25,028	61,782
(Gain) loss on sale of fixed assets and investments	'	'	-6,086	-31,674
Cash outflow from hedging	'	'	'	11,256
Dividend income from equity method investees	'	'	11,965	'
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Trade accounts receivable, net	'	'	-32,888	19,309
Inventories, net	'	'	-41,613	-19,777
Prepaid expenses, other current and non-current assets	'	'	144,519	3,468
Accounts receivable from/payable to related parties	'	'	-202,653	104,633
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	41,288	12,220
Income tax payable	'	'	3,837	1,257
Net cash provided by (used in) operating activities	'	'	1,208,474	1,413,729
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	-483,424	-420,367
Proceeds from sale of property, plant and equipment	'	'	18,098	10,965
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	-292,784	-1,787,208
Proceeds from divestitures	'	'	17,984	'
Net cash (used in) provided by investing activities	'	'	-740,126	-1,964,863
Financing Activities:	'	'	'	'
Short-term borrowings, net	'	'	94,366	67,723
Long-term debt and capital lease obligations, net	'	'	-2,309,633	-844,418
Increase (decrease) of accounts receivable securitization program	'	'	37,000	12,500
Proceeds from exercise of stock options	'	'	6,298	17,589
Payment of dividends [N]	'	'	-2,861	-240
Capital (decrease) increase	'	'	1,742,265	1,576,424
Distributions to noncontrolling interests	'	'	162,239	-131,783
Contributions from noncontrolling interests	'	'	52,357	15,167
Net cash (used in) provided by financing activities	'	'	-542,447	712,962
Effect of exchange rate changes on cash and cash equivalents	'	'	-14,243	-2,814
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	-88,342	159,014
Cash and cash equivalents at beginning of period	'	'	686,457	457,145
Cash and cash equivalents at end of period	598,115	616,159	598,115	616,159
Combining Adjustment [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	-1,287,642	-1,563,115
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	'	'	1,141,758	1,475,632
Depreciation and amortization	'	'	-24,284	-21,496
Change in deferred taxes, net	'	'	-13,513	-5,669
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Inventories, net	'	'	24,714	13,089
Prepaid expenses, other current and non-current assets	'	'	-1,061	68
Accounts receivable from/payable to related parties	'	'	101,988	60,572
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	-3,004	-1,466
Income tax payable	'	'	7,020	-23,866
Net cash provided by (used in) operating activities	'	'	-54,156	-66,251
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	27,537	29,622
Disbursements of loans to related parties	'	'	-653,057	-931,849
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	33,058	1,612,807
Net cash (used in) provided by investing activities	'	'	-592,462	710,536
Financing Activities:	'	'	'	'
Long-term debt and capital lease obligations, net	'	'	653,057	931,849
Payment of dividends [N]	'	'	2,861	240
Capital (decrease) increase	'	'	-10,303	-1,576,424
Net cash (used in) provided by financing activities	'	'	645,615	-644,335
Effect of exchange rate changes on cash and cash equivalents	'	'	'	0
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	-1,003	-50
Cash and cash equivalents at beginning of period	'	'	'	0
Cash and cash equivalents at end of period	$0	'	$0	'